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Abstract 
Epidemiology, Molecular Characterisation and Tropism 
of the Hepatitis G Virus / GBV-C 
The hepatitis G virus and GBV-C are recently discovered variants of the same 
virus belonging to the family Flavivirus (HGV/GBV-C). Although initially thought 
to be a hepatitis virus, it has been shown to have no association with liver 
disease. No work has been performed on the prevalence or molecular 
characteristics of HGV/GBV-C in southern Africa. In addition, although it is clear 
that the liver is not the primary site of replication, there is no data on the sites of 
HGV/GBV-C replication in normal subjects. Thus, this study aimed to assess the 
prevalence of HGV/GBV-C carriage in the urban and rural adult Black 
communities of the Western and Eastern Cape Provinces of South Africa, and 
compare it to the prevalence of serological markers of the hepatitis viruses A-E. 
In addition, this study aimed to assess the molecular features of South African 
HGV/GBV-C isolates and demonstrate the organs where viral replication was 
present. 
The mean prevalences of antibodies to hepatitis A lgG, hepatitis B surface 
antigen and antibodies to hepatitis B surface antigen were 98%, 4.3% and 61.1 % 
respectively. The mean prevalence of antibodies to hepatitis C was 1.8%. No 
significant differences in prevalence were shown between the urban and rural 
regions for these viruses. The mean anti-hepatitis E prevalence varied from 
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5.8% to 19.1 % in the different regions. Those living in mud houses without 
access to chlorinated tap water had a significantly higher prevalence of anti-
hepatitis E. No anti-hepatitis D positive samples were isolated. The overall 
prevalence of HGV/GBV-C was 26.9%, with rural communities having a 
significantly lower prevalence than urban communities. A significant relationship 
was observed between HGV/GBV-C infection with the use of illicit drugs, female 
gender, younger age and past blood transfusions. 
Phylogenetic analysis demonstrated a novel fourth South African HGV/GBV-C 
genotype, distinct from the previously described genotypes 1-3. In addition, 
certain isolates showed a major deletion in the highly conserved 5' non-coding 
region of HGV/GBV-C. Analysis of 23 tissue biopsies from infected cadavers 
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The history of the hepatitis G virus and GB virus C is integrally linked to liver 
disease as a consequence of the clinical settings within which they were isolated, 
as well as the global investigations that followed their isolation within the 
disciplines of hepatology and virology. 
The final chapter of this thesis contains data that joins other international 
researchers who argue that these viruses have at best, a tenuous link to the liver 
and liver pathology. However, as they have their origins firmly within the world of 
hepatovirology, the data on the hepatitis G virus and GB virus C is preceded by 
an assessment of the prevalences of hepatitis A-E in the same communities. 
A literature review relating to GB virus C and the hepatitis G virus is found in 
chapters 2, 3 and 4 of this thesis. In keeping with the work to be presented, the 
review is divided by chapter into the following components: 
• General introduction and epidemiology; 
• Molecular characterisation; and 
• Tropism of the hepatitis G virus and GB virus C. 
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CHAPTER 1 
Background prevalence of hepatitis 
A, B, C, D and E in the Western- and 




The hepatitis viruses isolated to date are hepatitis A, B, C, 0 and E. There is no 
data on the prevalences of these viruses in the Western and Eastern Cape 
Provinces of South Africa. Thus, this study aimed to assess exposure to hepatitis 
A, B, C and E in adult Black South Africans, as well as the rate of HOV co-
infection amongst HBV carriers. 
Volunteers were recruited for the hepatitis A, B, C and E study from the out-
patient department queues of state clinics in two urban and two rural 
communities. For comparison, further volunteers were recruited for the same 
study in a community sampling procedure. A standard questionnaire was 
administered to each person for demographic data and potential risk factors for 
hepatitis virus infection. For the HOV study, anti-HOV was assessed in a 
separate group of HBV positive individuals. Testing for markers of hepatitis A-E 
infection was performed with commercial assays. 
A group of 767 people were studied for hepatitis A, B, C and E markers of whom 
407 (53%) were from the two urban areas and 360 (47%) from the two rural 
districts. The mean prevalences of anti-HAV lgG, HBsAg and HBsAb were 98%, 
4.3% and 61 .1 % respectively. The mean prevalence of anti-HCV was 1.8%. No 
significant differences in prevalence were shown between the urban and rural 
regions for these viruses and none of the questionnaire variables were 
significantly associated with infection. 
20 
The mean anti-HEV prevalence was 10.7% and varied from 5.8% to 19.1% in the 
different regions. The mean urban and rural rates of 6.6% and 15.3% 
respectively were significantly different (p= 0.0001 ). Further analysis of the rural 
group showed that those living in mud houses without access to chlorinated tap 
water had a significantly higher prevalence of anti-HEV than those living in the 
rural villages where drinking water was chlorinated (17.4% vs. 5.3%). The use of 
pit latrines was shown to be associated with anti-HEV seropositivity (p=0.0013), 
while those using toilets with water borne sewerage were at a lower risk of HEV 
infection (p=0.0017). None of the 247 sequential HBsAg positive serum samples 
were anti-HOV positive. 
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1.2 Background on viral hepatitis 
The number of known hepatitis viruses is increasing as more sophisticated 
molecular techniques permit the detection, isolation and characterisation of these 
agents. The viruses that cause hepatitis can be divided into those that are 
primary hepatitis viruses, which have their primary site of replication in the liver, 
and other viruses that have the capacity to replicate in the liver, but are generally 
more prominent in other organ systems e.g. cytomegalovirus. The primary 
hepatitis viruses isolated to date are known as hepatitis A, B, C, D and E. Each 
is distinct from the others and from a different virus family. Although hepatitis C 
infection normally causes a mild hepatitis, all five viruses have the capacity to 
induce a spectrum of disease severity from subclinical to fulminant. As a 
consequence, it is not possible to distinguish between them on the basis of the 
clinical picture at the bedside. A final aetiological diagnosis is thus reliant on 
serological analysis of patients' serum (1,2) . 
The hepatitis viruses may be divided according to their mode of transmission: 
enterically- or parentally transmitted. 
1.2.1 The enterically-transmitted hepatitis viruses 
1.2.1.1 The hepatitis A virus: 
The hepatitis A virus (HAV) was initially identified by electron microscopy in 1973 
(3) and was shown to be a small, non-enveloped spherical virus with a single 
stranded RNA genome. HAV was initially thought to be a member of the genus 
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Enterovirus within the family Picornaviridae. However, molecular analysis has 
allowed for HAV to be placed in a genus of its own, Hepatovirus (4). 
HAV is transmitted by the fecal-oral route and is highly infectious (5,6). As a 
consequence, the epidemiology of HAV infection in developing countries differs 
markedly from more developed nations, on account of differences in living 
conditions. Developing country communities are infected at an early age due to 
persistent circulation of HAV between household members within poor 
communities. As a result almost all individuals in these communities show 
immunological evidence of past exposure to HAV by early childhood, as 
demonstrated by the presence of serum anti-HAV lgG (7) . As the vast majority of 
young children tend to have a mild (or subclinical) HAV disease, the burden of 
HAV in these communities is paradoxically low and epidemics virtually non-
existent due to the high herd immunity. In contrast, developed countries have a 
far lower percentage of the community infected with HAV, but have a higher 
disease burden, as the majority of infections occur in adulthood, where the 
disease is more serious (8). HAV epidemics are not infrequent in developed 
countries (8). 
A vaccine containing purified inactivated HAV is produced commercially for those 
at high risk of acquiring the disease due to work, travel or other reason that 
increases the risk of exposure to HAV. In addition, HAV transmission to 
household contacts can be prevented by the administration of pooled 
gammaglobulin to susceptible individuals (9). 
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1.2.1.2 The hepatitis E virus 
The hepatitis E virus (HEV), or enterically transmitted non-A non-B hepatitis, is 
the second of the enteric hepatitis viruses. It is a spherical, non-enveloped single 
stranded RNA virus that is placed within the family Caliciviridae and genus 
Hepatitis E-like Virus (4,10-12). 
HEV is the leading aetiological agent implicated in outbreaks of waterborne 
hepatitis in developing countries where sanitation is poor ( 13-15). However, HEV 
has also been found to be endemic in these regions and of late has also been 
shown to circulate in more developed countries (14-16) . Although less infectious 
than HAV, HEV is the leading cause of epidemic hepatitis in many under 
developed countries due to the high levels of HAV herd immunity, thereby 
preventing HAV epidemics (13) . 
The hepatitis E virus has been responsible for massive outbreaks of hepatitis in 
Asia and Africa (17-23). Travelers to these under-developed countries (24) and 
groups of people who reside together temporally, e.g. military personnel and 
refugees, are at increased risk of contracting HEV (23,25). Medical staff 
attending patients with HEV infection have also been infected (26) . Sporadic 
hepatitis due to HEV infection has been described in a variety of countries, where 
both adults and children are susceptible (27-30) . HEV has been documented in 
South Africa (26,31 ), but no data exists on the prevalence of anti-HEV in a 
representative sample of South African communities who are at greatest risk of 
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acquiring the disease, due to poor socioeconomic living conditions. As yet, there 
have been no documented epidemics of acute HEV in southern Africa. 
In most patients, HEV infection is a mild, self-limiting illness although fulminant 
hepatic failure has been reported (12,32). The disease is more severe in 
pregnancy, and particularly so when infection occurs in the third trimester, where 
the incidence of fulminant hepatic failure is as high as 20% (32) . In the Algerian 
outbreak of 1980/1 , 100% of pregnant women with acute HEV died (19) . This is 
significantly higher than the usual mortality quoted, but may be on account of the 
smaller numbers reported. The risk of intra-familial spread of HEV is significantly 
higher than for the general community (33), although substantially less than for 
HAV (34). 
HEV can be visualised during acute infection by electron microscopy in serum, 
faeces (and bile) (10,35), and is also detectable over a longer period using a 
polymerase chain reaction (PCR) assay (36). Serum is positive for lgM anti-HEV 
at the onset of acute illness, while lgG levels become detectable 6 to 10 days into 
the illness and last for many years (11 ,36). Liver biopsies taken years after the 
illness show no signs of chronic disease (37) , and no long term carriers of HEV 
have been documented. 
There are currently no commercial vaccines available for HEV, although success 
with experimental vaccines has been reported (38). There is little justification for 
the use of pooled immunoglobulin preparations for family contacts of patients, as 
the donated serum is frequently from first world countries where most have not 
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been exposed to HEV. In addition, immunoglobulin preparations from endemic 
regions are of doubtful benefit (12,39) . 
1.2.2 The parentally- transmitted hepatitis viruses 
1.2.2.1 The hepatitis B virus 
The hepatitis B virus (HBV) is a member of the family Hepadnaviridae and genus 
Orthohepadnavirus. It is a small (42nm) spherical virus that contains a partially 
double stranded, circular DNA genome that is surrounded by the highly 
immunogenic core protein, which in turn is encapsulated by the surface protein 
(40) . The virus was initially described as "Australia antigen", but was later found 
to have a global distribution and renamed HBV (41 ). Three types of HBV 
particles can be seen by electron microscopy: the "Dane particle" which is the 
complete virus, while the other two forms (spheres and tubules) are circulating 
excess surface antigen (HBsAg). 
The initial laboratory diagnosis of HBV is normally made by way of detecting 
circulating HBsAg. These assays are extremely sensitive, as there is excess 
surface protein that is detectable in almost all cases of infection (42). In a small 
proportion of acute infections, the diagnosis is made by detecting the anti-core 
lgM response which precedes the detectable surface antigen by a few days (43). 
Past exposure to HBV can be assessed by detecting antibodies to the surface 
antigen (HBsAb) or core protein (HBc) or both. The hosts' immune responses 
are sufficient to prevent re-infection and is life-long (44) . Mutant HBV has been 
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documented, with surface antigen mutants and pre-core mutants the most 
common (42,45). Of note, HBsAg mutants have been documented that do not 
react with adequately with certain commercial assays for the detection of HBsAg 
(42) . The soluble portion of the core protein is thee-antigen (eAg). The 
presence of eAg in the serum of an HBV infected individual is indicative of high 
levels of viral replication . Thee-antibody (eAb) is most frequently absent in the 
high replicative state. Seroconversion to an eAg negative, and eAb positive state 
is associated with lower replicative states of HBV (41). 
The clinical manifestation of HBV may be sub-clinical, mild, moderate or severe 
resulting in fulminant liver failure. The hepatitis severity seen in HBV infection is 
largely attributable to the magnitude of the immunological response of cytotoxic 
T-cells that destroy the infected hepatocytes (46). Mutant HBV (particularly pre-
core mutants) have been shown to be associated with a more severe illness (47). 
Chronic infection occurs in approximately 80-90% of children infected in the 
neonatal period or early childhood, and decreases to approximately 10-15% in 
adulthood (48) . In both children and adults, chronic HBV infection may result in 
cirrhosis and/or liver carcinoma (49). HBV-associated liver carcinomas are most 
frequently found to contain integrated HBV sequence within the host genome 
(50). Children suffer the long-term consequences of cirrhosis and hepatocellular 
carcinoma proportionately more commonly that those who acquire HBV in 
adulthood due to the increased rates of chronicity seen after infection in early 
childhood (50,51 ). 
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The epidemiology of HBV varies by geographical location. An estimated 300 
million people are infected with HBV globally, with sub-Saharan Africa one of the 
most affected zones (50,52). Many developing countries have high exposure 
rates at an early age, where HBV transmission frequently occurs horizontally 
between children and vertically from mother to child (53) . The Asian 
epidemiology of HBV infection in childhood differs from that seen in Africa, with 
vertical transmission common in Asia, and horizontal transmission frequently 
seen in Africa (53) . Adequate explanation regarding these differences in spread 
to (and between) children has been lacking to date. Developed countries have 
far lower prevalences of HBV and most infections occur in high-risk groups who 
are exposed to the virus either sexually or by the percutaneous route, often 
during intravenous drug usage (53). Blood transfusions were previously 
associated with transmission of HBV prior to the testing of blood donations, but is 
now a rare occurrence (54). 
There is limited data on HBV epidemiology in South Africa. Available information 
shows the HBV prevalence in adults to be >10% in certain communities (55), 
while children under the age of six years have been documented with a 
prevalence of approximately 10% (56). Gauteng, Kwazulu Natal and the Eastern 
Cape provinces are highly affected geographic regions that have been studied to 
date. Migrant mine workers having a prevalence of approximately 14% (56-58). 
It has been previously estimated that between 1.5 and 2 million individuals are 
HBV carriers in South Africa (58,59) , although more recent data is lacking. 
Clustering of infections within households has been documented, although the 
mechanism of transmission in these settings has yet to be shown (60). Children 
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are frequently infected early in life, most often acquiring the infection via 
horizontal transmission from other children (55,56,61 ). Perinatal transmission is 
far less common than in Asia (55). 
The most efficient mode of preventing HBV transmission is to vaccinate all 
individuals in the community (62,63). Universal vaccination for HBV was 
incorporated into the South African Expanded Program on Immunisation in 1995. 
This strategy has been shown to reduce the prevalence of HBV in endemic 
regions (64) . Vaccination is performed using either a plasma-derived vaccine 
that contains HBV surface antigen, pre-S1 and pre-S2, or with a recombinant 
vaccine containing surface antigen that is (normally) produced in recombinant 
yeast expression systems. Newer trivalent recombinant vaccines are expected to 
be more immunogenic and replace the mono-valent vaccines currently available. 
Sexual transmission is prevented by way of protected intercourse between 
couples (53). Blood products are screened for HBV and discarded if infected. 
Perinatal transmission is dramatically reduced with administration of HBV 
immune globulin at birth to children of infected mothers, followed by active 
vaccination thereafter (65). 
1.2.2.2 The hepatitis D virus (Delta agent) 
The hepatitis D virus (HOV) is an incomplete RNA virus that is placed within the 
family Arenavirus and genus Delta virus. HOV is entirely dependent on prior or 
co-infection with HBV for survival , as it uses the surface antigen of HBV as its 
envelope to prevent degradation (66). The HOV infects hepatocytes and causes 
a chronic infection along with HBV. Super-infection of HBV with HOV often 
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results in a worsening of the patients condition, and co-infection with HBV and 
HOV may result in a more severe disease state than infection with HBV alone 
(67). 
There is currently no evidence for HOV infection in the HBV-infected community 
of South Africa. The work by Ousheiko et al (1989) and S.S, Abdool Kariem et al 
(1991) (58,68) showed HOV infection to be extremely rare. A conference 
abstract report in a 1997 supplement of the South African Medical Journal gave 
evidence of HOV introduction into the South African HBV infected community with 
an 80.4% prevalence in HBV positive individuals from Pretoria and Ga-Rankuwa. 
However, this data was later (partially) retracted, both in the press and by way of 
personal communication (S. Aspinall , Medical University of South Africa) (in 
response to reference number 69). The above conference report encouraged a 
formal assessment of the situation in the Free State Province, where no HOV 
infection was demonstrated (70). 
There is no treatment for HOV infection. HOV/HBV infected individuals progress 
to cirrhosis more rapidly than those infected with HBV alone (67) . However, 
those who are co-infected appear to have better survival rates after liver 
transplantation than those who are infected with HBV alone (71 ). HOV 
prevention measures are the same as for HBV, as preventing HBV infection 
results in fewer HOV-susceptible individuals. 
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1.2.2.3 The hepatitis C virus 
The term, "the hepatitis C virus (HCV)" was coined after the discovery of the HCV 
genome in 1989 (72,73) . However, the existence of this agent had been 
presumed with the ongoing hepatitis cases, after the establishment of adequate 
assays for HAV and HBV (74). This "agent" was initially termed "post-transfusion 
hepatitis", as it was well documented that there was at least one further 
transfusion-transmissible agent that caused hepatitis, after the exclusion of those 
donations infected with HBV (and HAV). 
The HCV genome was detected in serum after the screening of complementary 
DNA (cDNA) clones generated from patients suspected of being carriers of the 
"post-transfusion hepatitis virus" (72) . Sequencing of overlapping clones resulted 
in the identification of the complete HCV genome, that was shown to be a 
positive strand RNA virus with close resemblance to the members of the family 
F/aviviridae. Extensive investigation of the molecular structure of HCV has 
resulted in its placing as a separate genus Hepacivirus (4,75). Current 
recommendations of the International Committee on Taxonomy of Viruses (ICTV) 
are that the older "genotype" system of phylogenetic analysis be replaced by a 
"clade" system comprising clades 1-6 (75) . Genotypes 1,2,4 and 5 will be named 
clades 1, 2,4, and 5 respectively, while genotypes 3 and 1 O will be placed in 
clade 3. Glade 6 will comprise genotypes 6, 7, 8, 9, and 11 . 
The hepatitis induced by HCV is generally a mild disease, and many infected 
individuals do not give a history of being at-risk of acquiring HCV through blood 
products, intravenous drug use, dialysis, etc (76-78). On account of its mild 
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nature, many of those infected with HCV are only found on routine screening 
through the blood banks. Although the infection may present as a mild disorder, 
most go on to chronic infection (77, 79). Chronic infection is associated with 
cirrhosis and liver carcinomas (79). The mechanism by which HCV induces 
carcinomas is not fully identified. However, the HCV genome is not integrated 
into the host genome, as is seen with HBV (79). 
Diagnosis of HCV infection is normally performed in routine laboratories by 
initially screening with third generation anti-HCV assays. There is no laboratory 
standard for testing of antibodies to HCV. Thus sensitivity and specificity 
measurements are not exact. However, third generation assays containing four 
recombinant antigens are considered to be highly sensitive and specific, based 
on the data from known HCV seroconvertions. The earlier generation assays 
that used fewer recombinant antigens gave both false positive and false negative 
results (80). Viraemia detection is normally only performed on anti-HCV positive 
samples and is detected by PCR amplification of a segment of the genome, after 
reverse transcription (RT) of the RNA genome into cDNA. For cases where the 
antibody assays give indeterminate results, a further recombinant immunoblot 
assay (RIBA) may be performed to assess the nature of the antibody response 
(81 ). RIBA results appear to correlate well with PCR for the purpose of screening 
large populations for viraemia (80). 
There is limited data on HCV infection in South Africa. The community 
prevalence of anti-HCV in Kwazulu Natal was shown to be 0.9% and 1.7% in 
rural and urban communities respectively (82) , and this is in keeping with data 
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from a smaller study of maxillofacial patients at Medunsa Dental Hospital where 
the prevalence was 1.1 % (83) . The prevalence of anti-HGV in donors of the 
Western Province Blood Transfusion Service (WPBTS) was shown to be 0.41 %, 
using a second generation anti-HGV assay (78) . Dialysis patients in South Africa 
have been shown to have a prevalence in excess of 20% in two haemodialysis 
units in South Africa (84) . Glade 5 HCV predominates in South Africa (85). 
Glade 5 is implicated in the genesis of liver carcinomas, but to no greater or 
lesser extent than any other HCV clade (86). 
1.2.3 Additional hepatitis viruses 
It is presumed from epidemiological evidence that there is at least one further 
hepatitis virus (87-89). This is based on the finding that post transfusion hepatitis 
remains prevalent, even after the exclusion of the known hepatitis viruses. No 
other proven hepatitis viruses have been isolated to date, although the newly 
discovered "transfusion transmitted virus (TTV)" is currently being investigated as 
a possible cause of hepatitis (90) . However, the high prevalences of this virus in 
the general community suggest that it likely to play a minor role in disease 
induction (91-93). 
1.3 Study rationale 
No systematic analysis of the epidemiology of hepatitis viruses A-E has been 
performed in the Western and Eastern Cape Provinces of South Africa. In 
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addition, at the time of setting up the study, no data was available on the 
prevalence of HEV in sub-Saharan Africa. 
1.4 Aims 
This study aimed to assess: 
1. the background prevalence of hepatitis A, B, C and E in rural and urban adult 
Black South Africans living in the Western and Eastern Cape Provinces of 
South Africa. The study was designed to detect differences in hepatitis virus 
exposure between rural and urban groups, and sought to identify factors 
associated with an increased risk of infection. 
2. the prevalence of HOV co-infection amongst HBV carriers of the Western 
Cape Province. 
1.5 Materials and methods 
1.5.1 Institutional approval 
Both studies below were approved by the Ethics and Research Committee of the 
Faculty of Health Sciences of the University of Cape Town. Study 1 also had 
approval from the regional health authorities responsible for the clinics where the 
volunteers were recruited. 
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1.5.2 1: Hepatitis A, B, C and E study 
1.5.2.1 Community support and permission for random sampling 
Access to the rural villages for the random sampling in the Keiskammahoek 
district was negotiated with the elected community leaders, in consultation with 
the local Community Health Department of the S.S. Gida Hospital , 
Keiskammahoek. 
1.5.2.2 Communities sampled 
All recruiting was performed by the candidate within selected communities of the 
Western and Eastern Cape Provinces of South Africa with assistance from study 
nurses and students who administered the questionnaire. 
Two urban and two rural communities were chosen for the study: 
Urban communities: 
• The urban suburbs of Nyanga and Guguletu were chosen in Cape Town. 
• The urban region of Mdantsane was chosen in East London. 
The volunteers from both cities lived in both the formal housing sector and 
informal squatter communities. 
Rural communities: 
• The rural town and surrounding villages of Keiskammahoek; and 
• the rural village of Peddie, in the Eastern Cape Province were designated as 
a suitable comparison sites for rural sampling. 
This sample group included people living in formal housing within the towns, as 
well as those living as subsistence farmers in isolated clusters of traditional mud 
house villages. 
35 
1.5.2.3 Sampling methods 
The recruitment of volunteers willing to participate and donate blood samples was 
performed in two phases. 
Phase 1 : Out-patient department sample group: 
The first phase was performed identically in the outpatient department (OPD) 
cl inics of the: 
• S.S. Gida Hospital of Keiskammahoek; 
• Nompumelelo Hospital of Peddie; 
• Cecelia Makiwane Hospital in Mdantsane, East London; 
• Nyanga and Guguletu Day Hospitals of Cape Town. 
Those recruited in these four health centres were sequential , consenting adults 
attending non-specialist OPD clinics of state-run health facilities. The patients 
were attending the clinic for routine management of their medical problems, and 
not for the purposes of the study. 
Phase 2: Random community sample: 
The second phase of sampling was performed to assess any differences 
between the OPD group and the general community for HEV (and HGV/GBV-C). 
In this separate, random, community-based study, a sample population of 160 
persons was recruited in Keiskammahoek. The random collection of volunteer 
samples was performed in the following manner: 
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• Keiskammahoek is divided into 45 regions by the local health authority (as 
shown in appendix 1 ). Four of these regions were selected as sampling 
areas, using a random number chart after assigning numbers to the regions. 
• Within these chosen regions, plots of approximately half an acre in size 
(independent of the number of houses on each plot) were considered to be a 
sampling unit. 
• An aerial photograph was obtained of the relevant villages and plots were 
numbered on the photo. 
• The starting plot for sampling was chosen with the aid of a random number 
chart and every second unit was sampled until a total of 40 people were 
included i.e. a total of 160 individuals in the four districts. 
• Eligible, consenting occupants of each unit were numbered and a maximum 
of two volunteers were chosen per unit (by random number chart) . 
1.5.2.4 Volunteer consent 
It was predicted that many of those that we aimed to recruit to the study would be 
either illiterate, or have poor literacy levels. Thus, the university ethics committee 
and the local authorities granted permission for the volunteers to give verbal 
consent at the time of entry into the study. The interviews were performed by 
Xhosa-speaking medical students and nurses dedicated to the study. The 
persons interviewing the volunteers standardized the questionnaire and 
confirmed that each person was asked the questions in an identical manner. 
The nature of the study was explained to potential OPD volunteers in a private 
room adjacent to the queues of the clinics. The same informed consent process 
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was performed during the community sampling, with as much privacy as possible 
in the individuals' homes. No person was coerced into participating, and all 
volunteers were informed that they would not receive the results individually. 
However, the community leaders were given the assurance that epidemiology 
results would be fed back to the local hospital authorities. 
1.5.2.5 Inclusion and Exclusion Criteria 
Volunteers were included in the study if they were resident in the relevant sample 
area for a minimum of five years prior to inclusion. "Residence" was defined as 
living in the region for a minimum of nine months in each of the five years. All 
volunteers were 18 years or older, and ambulant. 
1.5.2.6 Questionnaire 
A standard questionnaire was administered to each person recruited to the study. 
This elicited information regarding age, gender, house type (brick, corrugated iron 
or mud), source of household water (tap or river), mode of sewerage disposal, 
employment, a history of hepatitis or any form of liver disease, past transfusions, 
scarification (i.e. ritual scarring) and a history of significant trauma requiring 
hospitalisation. 
Patients attending the OPD were also questioned about the quantity of alcohol 
consumed and the use of illicit drugs. For the purposes of this study habitual 
consumption of >60g of alcohol per day or >360g alcohol per weekend was 
considered excessive [Grnnbffik et al. , 1994; Becker et al., 1996]. Data on 
alcohol consumption and drug use was not collected during the door-to-door 
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community sampling in Keiskammahoek because of resistance voiced by the 
community leaders when negotiating access to the villages. The community 
leaders stated that, as the houses of the region were almost invariably single-
roomed, the privacy of the individual was not guaranteed during the interview and 
thus a) the answers to the questions may be incorrect and, b) the process may 
compromise the person being interviewed. 
1.5.2.7 Sample preservation 
Two 10ml tubes of blood were taken from each volunteer in a glass Vacutainer 
tube (Beckton Dickinson, France) containing no additives. The blood was 
allowed to clot and the tubes centrifuged at 3000 revolutions per minute for 10 
minutes, within four hours of sample collection. The serum was transferred to 
separate storage tubes and placed at -20°C. On returning to the laboratory, 
these were then transferred to a -80°C freezer for long-term storage. The 
samples remained in the -80°C freezer and were not thawed until processed for 
this study. 
1.5.3 2: Hepatitis D virus study 
1.5.3.1 Sample site 
The combined Virology Laboratory of the Groote Schuur Hospital and the South 
African Institute for Medical Research was used as a source of HBV positive 
samples for the study. 
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Sequential HBsAg positive serum samples received by the laboratory were 
prospectively collected for inclusion in the testing and analysis. This combined 
laboratory was chosen as it services an extremely wide range of clinics and 
hospitals. The samples were from children and adults with both acute and 
chronic hepatitis from all levels of the Western Cape health structure, from 
primary health facilities to specialist hepatology clinics. 
1.5.3.2 Laboratory methods 
The prevalence of hepatitis markers was determined with standard commercial 
assays for each virus. Each assay was performed in accordance with the 
manufacturers' instructions. 
The following assays were used: (All assays were from Abbott Laboratories, 
North Chicago, USA, except where indicated). 
• Anti-HAV lgG was assessed with the HAVAB-G radio-immunoassay. 
• HBsAg was detected using the AUSRIA assay. 
• HBsAb was detected with the AUSAB assay. 
• HBeAg and HBeAb were detected with the HBeAg and anti-HBe radio-
immunoassay respectively. 
• Anti-HCV was determined by both Ortho and Behring second generation EIA's 
(Ortho Diagnostics, Raviran, NJ, USA; and Behringwerke AG, D-35001, 
Marburg), and only considered positive when repeatedly reactive with both 
assays. (Third generation anti-HCV assays only became available in South 
Africa after this testing was complete) . 
• Anti-HOV lgG was detected using the anti-Delta EIA. 
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• The HEV enzyme-linked immunosorbent assay was used to test all samples 
for anti-HEV lgG in duplicate. The test was repeated again if the result was 
indeterminate. Samples were only considered true positives when repeatedly 
reactive. 
1.5.3.3 Statistical methods 
Statistical analysis was performed using the Epi-lnfo version 6 software program 
(Center for Disease Control , GA, Atlanta, USA) and the Statistica software 
program (Statsoft, Tulsa, USA). Differences in prevalence were analysed using 
the Chi squared test. Discriminant analysis by stepwise method assessed factors 
associated with increased risk of infection. The linear model was used to 
estimate whether gradients differed significantly. 
1.6 RESULTS 
1.6.1 1: Hepatitis A, B, C and E study 
A cohort of 767 people were studied, of whom 407 (53%) were from the two 
urban areas and 360 (47%) from the two rural districts. Two hundred and eighty 
(68.8%) urban dwellers lived in formal housing, while the remainder were from 
urban squatter settlements. The rural OPD sample size was 200, while the 
random community sample size was 160. Seventy percent (252) of the rural 
group lived in traditional mud houses, with inadequate sewerage disposal and no 
access to chlorinated tap water. The average age of the entire sample was 42.4 
years (range 18-92), and the male:female ratio was 1: 1.8. 
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1.6.1.1 Hepatitis A 
The mean prevalence of anti-HAV lgG was 98%. The graph below (Figure 1.1) 
shows the anti-HAV lgG prevalences were for the four regions. No statistically 
significant differences were detectable between the regions. None of the 
questionnaire variables were significantly associated with past infection. 
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1.6.1.2 Hepatitis B 
The mean prevalences of HBsAg and HBsAb were 4.3% and 61 .1 % respectively. 
The following two graphs (Figures 1.2 and 1.3) demonstrate the HBsAg and 
HBsAb prevalences in the four communities. No differences were shown 
between the regions for either of these variables or for the total exposure to HBV; 
i.e. the summation of the two. None of the questionnaire variables were 
significantly associated with either current or past HBV infection. 
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Figure 1.2: Prevalence of HBV surface antigen. 
O/o 2 
Hepatitis B surmce antigen carriage 
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II Urhm (East London) I Urban (Gtpe Town) 
Figure 1.3: Prevalence of antibodies to HBV surface antigen. 
Ofo 
Hepttitis B surface antibody 
D Rural (KKH) I Rural (Peddie) 
I Uibm (East Lomon) I Uibm (Gtpe TOffll) 
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HBeAg and HBeAb status of the HBV positive samples showed 12.5% to be eAg 
positive and eAb negative, while 87.5% were eAg negative and eAb positive. 
None of the samples were positive for both eAg and eAb serum markers. 
1.6.1.3 Hepatitis C 
The mean prevalence of anti-HCV was 1.8%. The following graph (Figure 1.4) 
shows the prevalence of anti-HCV in the four communities. The number of 
positive samples was too small to detect statistically significant differences 
between the four communities, and none of the questionnaire variables were 
significantly associated with detectable serum anti-HCV. 
Figure 1.4: Prevalence of antibodies to HCV. 
o/o 
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I Uhm {fillst Lcnm) I Uhm (()qr Tomi) 
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1.6.1.4 Hepatitis E 
The mean anti-HEV prevalence was 10.7% and varied from 5.8% to 19.1% in the 
different regions. The mean urban and rural rates below (Figure 1.5) of 6.6% and 
15.3% respectively were significantly different (p= 0.0001). 
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Further analysis of the two rural groups showed that rural living alone was not the 
true association with HEV infection. Those living in mud houses without access 
to chlorinated tap water had a significantly higher prevalence of anti-HEV than 
those living in the rural villages where drinking water was chlorinated (17.4% vs. 
5.3%) (p = 0.008: odds ratio= 2.85) (Figure 1.6). Thus, those rural inhabitants 
with access to chlorinated tap water had an identical prevalence to the urban 
dwellers. 
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No differences in prevalence were found between the out-patient based and 
community based sampling. No significant differences were noted between the 
urban squatter and urban formal housing groups for any of the hepatitis markers 
(p > 0.05). 
Univariate analysis for anti-HEV 
The use of pit latrines was shown to have an association with anti-HEV 
seropositivity (p=0.0013), while those using toilets with water borne sewerage 
were at a lower risk of HEV infection (p=0.0017). Extremely few gave a history of 
hepatitis or any form of liver disease, suggesting a high degree of subclinical or 
low grade hepatitis. 
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Multivariate analysis for anti-HEV 
Discriminant analysis of all recruits showed rural location (0.364), age (0.589), 
living in mud houses (0.450) and a lack of access to chlorinated tap water (0.188) 
to be predictors of anti-HEV positivity (standardised coefficients in brackets). 
Discriminant analysis of the rural group alone confirmed a greater risk for mud 
hut dwellers. 
A linear relation was found between anti-HEV seroprevalence and age. When 
individual communities were examined, this relationship was maintained 
wherever sufficient positives allowed such analysis. 
1.6.2 2: Hepatitis D virus study 
The study assessed 247 sequential HBsAg positive serum samples, of which: 
• 69 were eAg positive and eAb negative, 
• 167 eAg negative and eAb positive, 
• 11 were positive for both eAg and eAb. 
None of the 247 samples were anti-HOV positive. 
1.7 DISCUSSION 
The hepatitis A and B results demonstrate exposure levels in keeping with the 
data reviewed in the introductory components of this chapter, showing that there 
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is almost universal (past) exposure to HAV and very high levels of HBV infection 
in the adult Black South African population. Most HAV infections occur in the first 
years of life amongst Black South African communities (94 ), and therefore it is 
likely that the anti-HAV prevalence results would have been as high even with a 
younger volunteer group from the same communities. HBV carriage rates appear 
to be lower than the figures for Gauteng, Kwazulu Natal and Namibia (57,60,94-
96) , but did not show significant variation between the urban and rural regions. 
The lack of a history of symptomatic hepatitis would suggest that the majority of 
infections occur in the absence of clinical hepatitis. The eAg/eAb results for the 
HBsAg positive individuals show the majority of HBV infected individuals to be 
eAg negative and eAb positive; highly suggestive of low replication rate of HBV. 
There is little data for comparison of HCV infections in the Western and Eastern 
Cape Provinces. However, it is noteworthy that the prevalence of antibodies to 
HCV in this community (1 .8%) is significantly higher than that of the blood donors 
of the Western Cape Province (0.41 %) (78) . Although different commercial anti-
HCV assays were used for these studies (Abbott versus Behring and Ortho), the 
laboratory methods are directly comparable, as both were performed just prior to 
the release of the third generation anti-HCV assays in South Africa. No HCV 
infections were detected in the East London group of 172. However, there was 
no statistically significant regional variation. 
This study found none of the Western Cape HBV positive samples to be HOV co-
infected. The 1997 conference report by Faber et al. alerted South African 
virologists to the possibility that HOV infection had become common amongst 
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HBV infected individuals in the Gauteng Province. The Western Cape data 
contained in this thesis is in keeping with the recent Free State Province data 
also showing no HOV infection in their group of HBV positive patients (70). The 
partial retraction of the initial data by Faber et al. (69, 70) suggests that HOV 
prevalence remains at an extremely low level in the community. 
The data show the prevalence of anti-HEV in adult Black South Africans to be 
higher than expected, given that no epidemics of HEV have been documented in 
South Africa. The rural prevalence was significantly higher than the urban 
prevalence. However, subgroup analysis of the rural group alone showed that 
there was a distinct difference between those with access to chlorinated water 
and those who collected water from nearby rivers. The prevalence amongst 
those with access to tap water in the rural regions was the same as the urban 
group. However, persons living with no access to chlorinated water had a 2.85 
fold increase in the risk of being anti-HEV seropositive. 
The univariate and multivariate analyses give evidence for increased 
transmission of HEV in the absence of adequate sewerage disposal. This is in 
keeping with the knowledge that HEV is transmitted by contact with faeces 
containing HEV. It is interesting to note that, although HAV and HEV are both 
transmitted by the fecal-oral route, their seroprevalence rates differed significantly 
in this study. The prevalence of anti-HEV increased linearly with age, strongly 
suggesting that there has been no recent epidemic outbreak of HEV in the 
communities sampled and thus that infection is sporadic. 
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The lack of difference in prevalence between the urban formal and urban squatter 
communities was surprising in view of the poor living conditions and the use of 
non-waterborne sewerage disposal methods within the majority of squatter areas. 
However, unlike their rural counterparts who use river water for consumption, 
urban squatter communities rely entirely on chlorinated tap water for domestic 
use, even if that water is brought to the house from a nearby tap in a container. 
In summary, this study has shown that the adult Black communities of the 
Western and Eastern Cape Provinces of South Africa have a very high exposure 
rate to the known hepatitis viruses. HAV exposure is almost universal , while 
hepatitis B carriage of approximately 3% to 5% is lower than for other provinces. 
However, overall exposure to HBV is over 60% in all regions studied. HCV 
exposure is 1.8%, which is significantly higher than the figure for blood donors. 
The prevalence of anti-HEV is significantly higher than expected, given that there 
have been no epidemics in the regions. In addition, evidence is presented to 
show that those with inadequate access to chlorinated tap water and waterborne 
sewerage were at increased risk of HEV acquisition. 
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CHAPTER 2 
Epidemiology of HGV/GBV-C viraemia 




The discovery of HGV/GBV-C and its published associations with hepatitis 
resulted in extensive research activity to assess its possible contribution to liver 
disease. However, no hepatitis-inducing role has been found for HGV/GBV-C. 
Global HGV/GBV-C prevalences differ significantly. Approximately 1-3% of the 
developed country inhabitants and between 5% and 18% developing nations are 
infected with HGV/GBV-C. Prior to initiating this study, no work had been 
performed on HGV/GBV-C in southern Africa. 
This study was performed on the same serum samples described in chapter 1. 
While the hepatitis A-E study evaluated four communities, the HGV/GBV-C 
assessment contained in this chapter investigated the samples from one urban 
and one rural community. A RT-PCR assay was developed for the 5'NCR of 
HGV/GBV-C. 
One hundred and thirty of the 484 samples were HGV/GBV-C PCR positive, 
giving an overall prevalence of 26.9%. The rural (20%) and and urban (34%) 
prevalences were significantly different (p=0.0005). Analysis of the questionnaire 
variables showed a significant relationship between HGV/GBV-C infection and 
the use of illicit drugs (marijuana), female gender, younger age and past blood 
transfusions. 
This data shows the prevalence of HGV/GBV-C in South Africa to be higher than 
any other published figure to date, excluding those studies assessing extremely 
high risk groups such as intravenous drug abusers. 
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2.2 Introduction 
After the discovery of the hepatitis A, B, C, D and E viruses, the presence of a 
further viral agent causing hepatitis was supported by the finding that many 
patients with an episode of clinical hepatitis had no known causative agent 
identified, in the presence of features compatible with viral infection (97,98). 
Thus, the discovery of two novel viral agents, GB virus C and hepatitis G, and 
their published associations with cryptogenic hepatitis caused an explosion of 
research activity by hepatologists and hepatovirologists assessing their possible 
contribution to liver disease. 
2.2.1 HGV and GBV-C discovery 
2.2.1.1 · GBV-C 
The first description of GBV-C was published in 1995 by Simons et al. after an 
extensive search for novel viral sequences by the Virus Discovery Group of 
Abbott Laboratories, North Chicago (102). One of the sera investigated by this 
group was that of a surgeon (initials GB) who had a clinical episode of hepatitis, 
later shown to be non-A-E hepatitis (99) . The serum was obtained from this 
surgeon on day 3 of his icteric illness (which occurred in the 1960s) and 
investigated over the following decades. The Abbott Laboratory research group 
inoculated this serum into tamarins and by a series of immunological and 
molecular processes, discovered three novel , putative viral genome sequences 
after 11 passages of the virus in these animals. The first of these two agents, 
GBV-A and GBV-B have been characterised and shown to be of primate (and not 
human) origin (100,101), while the third , GBV-C has been shown to infect a great 
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number of individuals globally (102,103). However, all three are related RNA 
viruses that are similar in genetic structure to previously described members of 
the family Flaviviridae, although distinct from HCV (104). 
2.2.1.2 HGV 
Another independent group of collaborators coordinated by Genelabs 
Technologies Inc., Redwood City, USA discovered similar but apparently novel 
viral sequences and published their results in 1996 (103) . The initial isolate was 
extracted from the serum of a patient with community-acquired chronic 
cryptogenic hepatitis. This serum was inoculated to tamarins, and like the serum 
from the surgeon (GB) above, caused hepatitis in the primates. Similar 
immunological and molecular biology technologies (such as immune-screening, 
anchored PCR and rapid amplification of cDNA ends) were employed to extract 
and expand upon the novel viral sequences, after the production of cDNA 
libraries (103) . The virus was named "hepatitis G" in the publication. 
The early molecular studies characterising GBV-C and HGV gave clarification 
that these were distinct from HCV. However, it was only established later that 
GBV-C and HGV were variants of the same novel flavivirus (105). Thus, for the 
purposes of this thesis, they will be named "HGV/GBV-C". Importantly, neither of 
the two, "hepatitis G" nor "GBV-C" have been accepted by the International 
Committee on Taxonomy of Viruses (ICTV). 
This chapter will review the natural history after infection with HGV/GBV-C as 
well as the epidemiology of HGV/GBV-C in different global communities and 
54 
assess the factors associated with increased risk of acquiring the infection. The 
review of the genetic components and tissue tropism of HGV/GBV-C is contained 
in chapters 3 and 4 of this thesis respectively. 
2.3 Natural history of HGV/GBV-C infection 
2.3.1 Transmission 
There have only been a limited number of studies performed to date assessing 
the natural history of HGV/GBV-C. However, HGV/GBV-C is known to be 
transmitted from person-to-person by the inoculation of blood products after 
transfusion(s) or by exposure to the virus during intravenous drug usage 
(103, 106-108). In addition, there is evidence showing that the virus can be found 
in saliva (103,106,109,110) and semen (111 ). Vertical transmission has been 
shown (112,113), and studies investigating sexual transmission of HGV/GBV-C 
suggest that the virus is also transmitted by sexual contact, with the receptive 
sexual partner at greater risk of acquiring the virus (113-115). 
2.3.2 Viral carriage and clearance 
Current evidence suggests that the majority of HGV/GBV-C infections result in 
chronic carriage of the virus, even in immunocompetent individuals (103, 116-
118). Most of the infected individuals show evidence of ongoing infection for a 
period of years, and if there is viral clearance, it is associated with the 
appearance of serum antibodies specific for the second envelope glycoprotein of 
HGV/GBV-C (anti-E2) (116,118-124). 
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The presence of anti-E2 is a marker of past infection, suggesting that this 
antibody is responsible (or partially responsible) for viral clearance (116,121,124). 
Large studies have repeatedly shown very few individuals to be positive for both 
markers of infection, and when both RNA and anti-E2 are demonstrated at the 
same time, it is normally interpreted as being indicative of a seroconversion 
process. In addition, studies have assessed the protective effect of detectable 
serum anti-E2 (125). These have shown that the presence of this antibody 
protects against re-infection with HGV/GBV-C. As discussed in chapter 3, the 
HGV/GBV-C genome has a conserved envelope coding (E1 and E2) region . 
Therefore unlike HCV, HGV/GBV-C has little ability to evade immune capture by 
altering the immunogenic epitopes. 
2.3.3 Animal models 
Animal studies of HGV/GBV-C using chimpanzee and tamarin infection models 
have not defined any disease association for this virus. However, the virology 
and immunology patterns demonstrated in these animal studies appear to mirror 
that seen in human infection with regard to infection routes and chronic viraemia 
(126). A newly discovered primate variant of HGV/GBV-C (named GBV-Ctro) 
has recently been discovered in chimpanzees and partially characterised (127). 
However, it has not been demonstrated to cause disease in these primates as 
yet. 
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2.4 HGV/GBV-C epidemiology 
The defining of global HGV/GBV-C infection patterns remains a "work-in-
progress". However, HGV/GBV-C prevalence studies have been conducted in 
countries from each continent and certain aspects regarding risk factors and 
infection patterns have been clarified. The majority of prevalence studies have 
been performed by hepatovirologists, based on the initial understanding that this 
virus was the latest of the primary hepatitis viruses. This is reflected in the bias 
towards studies assessing markers of infection in patients with liver disease. 
In keeping with the natural history of HGV/GBV-C reviewed above, studies have 
assessed either one or both of the following markers of infection: 
• viraemic status by RT-PCR, and/or 
• past infection, by detecting antibodies to the E2 protein. 
The following map (Figure 2.1) displays a selection of the published HGV/GBV-C 
prevalence figures, giving the RT-PCR (current infection) results for adults 
according to geographic region. Although all of the studies represented below 
used RT-PCR for assessment of viraemia, it is important to note that they were 
performed using different laboratory methodologies / commercial kits and with 
different sampling procedures for their study subjects, and therefore it may be 
argued that they are not directly comparable. In addition, much of the RT-PCR 
work presented in this map was performed shortly after the discovery of 
HGV/GBV-C and thus with limited knowledge of the genetic sequence of 
HGV/GBV-C. As a consequence, primer design may not have been optimal in all 
studies. Studies were only chosen for representation in the above diagram if they 
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were performed with the aim of elucidating the community prevalence of 
HGV/GBV-C, and not in a specific cohort of patients or at-risk groups. 
Figure 2.1: Prevalence of HGV/GBV-C viraemia. (Numbers in brackets 
represent the journal reference number). 
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Significant differences are evident from the figure between the developed and 
under-developed countries. It can be seen that the prevalence of HGV/GBV-C 
viraemia in developed communities of Europe, North America, and Australia 
varies between <1% and 3% (110,128,129). By contrast, the available 
prevalence data for developing nations in Africa, South America and parts of Asia 
show significantly higher rates of HGV/GBV-C carriage that range between 5% 
and 18% (130-133). 
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Fewer studies have assessed past exposure to HGV/GBV-C, as demonstrated by 
the presence of serum anti-E2 antibodies. However, where performed, the figure 
for past exposure is normally higher than that for viraemia (129,134,135). 
2.4.1 HGV/GBV-C risk factors 
The main routes of transmission and body fluids responsible for transmission of 
HGV/GBV-C have been mentioned above i.e. blood products and possibly semen 
and saliva. The data for HGV/GBV-C is in keeping with other viruses such as 
HBV and HCV that are transmitted parenterally. Those at highest risk of being 
exposed to HBV and HCV e.g. intravenous drug abusers, are those who show 
the highest exposure rates for HGV/GBV-C as well (136-138). Most groups of 
patients with repeated exposure to blood products, such as haemophiliacs show 
increased prevalences of HGV/GBV-C ( 139, 140). Interestingly, higher 
prevalence have even been shown for patients who have received virus-
inactivated blood products, therefore suggesting that HGV/GBV-C may be 
(partially) resistant to these treatments ( 136, 140). However, many infected 
individuals give no history of a known risk factor (141 ,142). 
Other HGV/GBV-C risk factors have also been identified in addition to those 
above: 
• Children of infected mothers are at risk of acquiring HGV/GBV-C by vertical 
transmission of the virus. These conclusions have been based on both the 
prevalence of comparative infant groups as well as molecular analysis of 
viruses extracted from the mother and infant (112,143). 
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• Both peritoneal and haemodialysis patients appear to have higher 
prevalences, and although certain studies have ascribed this phenomenon to 
the blood transfusions given to these patients, others studies show the 
infections to be independent of treatment ( 139,144,145). 
• Transmission of HGV/GBV-C from patients to staff may also occur. Needle 
stick injuries have resulted in transmission of the virus to health care workers 
(146), while certain institutions have shown higher prevalences of HGV/GBV-
C in dialysis staff (147). 
• HIV infected individuals in developed countries show increased exposure to 
HGV/GBV-C (137,148,149). However, this higher prevalence may be related 
to concomitant risk factors such as intravenous drug usage. 
• As discussed, intravenous drug abuse is a risk factor for HGV/GBV-C 
infection. Whi le the use of these drugs is very limited in South Africa (150) 
the principle of percutaneous trauma and carry-over of blood requires further 
investigation in the South African setting. There is widespread use of 
scarification (ritual or therapeutic scarring of the skin) in many Black 
communities. The cleanliness of the blades used in this procedure is often 
doubtful and carry-over of infected blood may occur. In addition, circumcision 
is a routine practice in much of southern Africa for men during initiation 
periods in adolescence. The blades used for these surgical procedures may 
not always be changed after each circumcision, thereby increasing the risk of 
viral transmission (151 ). 
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2.4.2 Association with liver disease 
2.4.2.1 Hepatitis 
Primary publications: 
The two primary publications describing the discovery of GBV-C and HGV both 
made the statement that the newly described viruses were associated with 
hepatitis (102,103). The first dealing with GBV-C (102) entitled, "Isolation of 
novel virus-like sequences associated with human hepatitis" investigated the 
serum sample from the surgeon (GB) and other sera from patients with non-A-E 
hepatitis. A significant (unspecified) proportion of these proved HGVIGBV-C 
PCR positive. 
The initial description of HGV (103) entitled, "Molecular cloning and disease 
association of hepatitis G virus: a transfusion-transmissible agent; described a 
significant positive association between HGVIGBV-C infection and post-
transfusion non-A-E hepatitis, chronic non-A-E hepatitis, acute non-A-E hepatitis, 
as well as co-infection with HBV and HCV. 
As a result of these two publications, many investigations followed which 
assessed liver patients, blood donors and the general community to confirm or 
refute this position. 
2.4.2.2 Later data: 
A proportion of the publications following immediately after the discoveries of 
HGV and GBV-C gave support for the initial hypothesis that HGVIGBV-C was 
responsible for inducing hepatitis. However, many had both selection and 
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methodological bias, as they frequently investigated hepatitis patients in the 
absence of adequate controls or without adequate investigation of risk factors 
(152,153). However, even studies with adequate controls included suggested 
that HGV/GBV-C may be implicated in the pathogenesis of non-A-E hepatitis 
(154). 
Most of the later studies have had more acceptable methodologies, and a greater 
proportion have sampled their study subjects prospectively. The majority of 
these have not shown an association with hepatitis ( 141 , 145, 155, 156). Two 
large clinical studies published in the New England Journal of Medicine stand out 
(141 ,156). The study by the "USA Sentinel Counties Study of Viral Hepatitis" 
assessed all samples from patients attending state health department clinics with 
acute hepatitis (156) . When the data was analysed and applied to all cases of 
acute hepatitis, only 0.3% of individuals were infected with HGV/GBV-C alone. 
This was not sufficient to implicate the virus in causing hepatitis, given the 
prevalence in the other groups. In the second study, H. Alter et al. assessed the 
role of HGV/GBV-C in post-transfusion hepatitis (141 ). It is clear from that data 
that HGV/GBV-C transmission to transfusion recipients is a frequent occurrence 
but that the virus is not a causative agent of post-transfusion hepatitis. In 
addition, when co-infected with HCV and HGV/GBV-C from the same blood unit, 
the presence of HGV/GBV-C did not worsen the clinical or biochemical hepatitis. 
In addition, many studies from different regions of the world including patients 
with all known HGV/GBV-C genotypes, have not shown an association between 
HGV/GBV-C infection and raised liver enzymes (157-159). Indeed, studies have 
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documented lower ALT values in infected than uninfected blood donors and 
patients (110,160). 
2.4.2.3 Co-infection with HAV, HBV and HCV 
Many cohorts have been studied to assess the natural history of chronic HBV and 
HCV using clinical, biochemical , histological and virological variables. The use of 
stored serum from these studies has allowed extensive retrospective analysis of 
the possible additional effect of HGV/GBV-C infection in addition to HBV or HCV. 
These studies have been uniform in their findings that super-infection or (co-
infection) with HGV/GBV-C has no effect on the liver using any one of the four 
variables above (158,161-163). The same findings apply in the post-liver 
transplant setting (164,165). 
The acute hepatitis study by M. Alter et al. using the "Sentinel Counties Study of 
Viral Hepatitis" samples also assessed the possible role of co-infection with 
hepatitis A, 8 or C and HGV/GBV-C (156). As with all other clinical settings, no 
hepatitis-inducing causative role could be found for HGV/GBV-C. 
2.4.2.4 Hepatocellular carcinoma 
The available published data suggests that HGV/GBV-C does not cause 
hepatocellular carcinomas. Studies from geographic regions representing all 
HGV/GBV-C genotypes have shown no association (166-170). In addition, co-
infection of HGV/GBV-C with either HBV or HCV did not appear to increase the 
carcinogenic potential of HBV or HCV (171 ). Only two studies have shown an 
association with hepatocellular carcinomas, but in both cases many of the 
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individuals were co-infected with either HBV or HCV ( 172, 173). While the 
authors of these two publications note the association, no attempt is made to 
designate this infection as being causative. 
2.4.3 Association with other diseases 
No disease has been consistently associated with HGV/GBV-C infection to date. 
There has been speculation that HGV/GBV-C infection is associated with 
haematological disorders such as lymphoma and myeloysplasia ( 17 4-176). 
However, although certain groups have shown this association, a causative 
mechanism has not been postulated and further work is required to confirm or 
refute this hypothesis. It has been postulated that HGV/GBV-C may play a role in 
renal disease independently of the frequent transfusions that many renal patients 
receive (144, 177-179). However, this also requires further in-depth assessment. 
2.4.4 Treatment 
No treatment for HGV/GBV-C is currently advocated, as there is no rationale for 
such intervention in the setting of no apparent pathogenic potential. 
Retrospective studies have investigated patients treated with interferon for 
chronic HBV or HCV infection who were co-infected with HGV/GBV-C (180). 
These show an apparent interferon-mediated HGV/GBV-C viral suppression, but 
a recurrence of viraemia in most cases after cessation of treatment. No other 
successful treatment schedules have been reported . 
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2.5 Study rationale and preliminary work 
No work has been performed on HGV/GBV-C infection in the Western- and 
Eastern Cape Provinces of South Africa to date, and prior to initiating the study, 
no work had been performed on this virus in southern Africa. 
This study, assessing HGV/GBV-C prevalence was divided into three distinct 
phases. Only phase 3 is presented in this chapter. 
• Phase 1 laboratory assessment of HGV/GBV-C carriage was performed on 
the serum samples collected in Keiskammahoek only. These preliminary 
results were published in the Journal of Medical Virology in 1997, volume 53; 
pages 225-228. This phase 1 RT-PCR and detection process was performed 
using the first generation Boehringer Mannheim (now Roche) Hepatitis G 
Virus primer and capture probe set (Roche Molecular Biochemicals, 
Germany). The nucleotide sequence of this set was based upon the 
HGV/GBV-C homology data available at the time. 
• In phase 2, contained in chapter 3 of this thesis, a portion of the 5'NCR of 
South African PCR positive samples was sequenced to ensure that the 5'NCR 
primers and probe were appropriate for South African variants of HGV/GBV-
C. The sequence data showed that the antisense primer used in phase 1 
needed modification, due to a lack of homology at five out of the 19 nucleotide 
positions. (This analysis was confirmed independently by Dr. V. Schlueter of 
the Roche Molecular Biochemicals group, who also generated sequence data 
on South African variants.) The antisense primer was substituted in phase 3 
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by another (42 bases upstream) that was shown to be homologous to all 
known variants. 
• This chapter contains the complete data generated during phase 3 with 
primers and probes that were homologous with all known (including South 
African) variants of HGV/GBV-C. Of note, the prevalence figures contained in 
this chapter differ significantly from that published in the preliminary analysis 
of phase 1 , due to the addition of more positive samples not previously 
detected. 
2.6 Materials and Methods 
2.6.1 Communities sampled 
This study was performed on the same serum samples from the Western and 
Eastern Cape Provinces, as described in the previous chapter of this thesis. 
However, while the hepatitis A-E study evaluated four communities, the 
HGV/GBV-C assessment contained in this chapter investigated the samples from 
one urban and one rural community. 
2.6.1.1 Western Cape 
The urban suburbs of Nyanga and Guguletu were chosen in Cape Town. The 
volunteers were from both the urban formal housing and informal squatter 
communities. 
2.6.1.2 Eastern Cape 
The Eastern Cape area of Keiskammahoek was chosen as the rural comparison 
site. As in chapter 1, this included people living in formal housing within the 
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Keiskammahoek town, as well as those living as subsistence farmers in isolated 
clusters of traditional mud house villages. 
2.6.2 Sampling methods 
The sampling methods are identical to that described in the previous chapter of 
this thesis for Keiskammahoek and Cape Town. The only exception is that two of 
the 251 Keiskammahoek samples contained insufficient serum for HGV/GBV-C 
analysis. Thus the rural group was reduced to 249 samples. 
2.6.2.1 Sample preservation 
The serum was stored at -80°C as described in chapter 1. Of note, the serum 
used for this HGV/GBV-C analysis was a different aliquot to that used for 
hepatitis A-E testing, and was only thawed for the first time for the HGV/GBV-C 
analysis. 
2.6.3 Reagents and Control Plasmas 
Unless otherwise stated, all reagents and HGV/GBV-C control sera used in this 
prevalence study were supplied (free of charge) by Boehringer Mannheim (now 
Roche) , Mannheim, Germany. The HGV/GBV-C control sera included RNA 
negative, low titre positive and high titre positive samples. 
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2.6.4 RNA Extraction 
RNA was extracted from 200µ1 serum using Total RNA Isolation Reagent 
(Advanced Biotechnologies Ltd, London, UK) according to the manufacturer's 
instructions. The RNA was precipitated in isopropanol overnight at -20°C, 
pelleted, washed with 75% ethanol and resuspended in 20µ1 diethyl 
pyrocarbonate (DepC) treated ultra pure water. 
2.6.5 cDNA synthesis 
A cDNA synthesis step was performed in a 20µ1 solution containing 1 OµI of the 
extracted RNA with final concentrations of 50nM random hexamers, 200µM PCR 
nucleotide mix, 1 U RNase inhibitor, 1 X reverse transcription (RT) buffer [50mM 
Tris-HCI, 8mM MgCl2, 30mM KCI , 1 mM dithioerythritol (pH 8.5)] and 10 U 
Maloney murine leukemia virus (MMLV) reverse transcriptase. This was 
incubated for 1 O minutes at room temperature, 30 minutes at 42°C and 5 minutes 
at 95°C. 
2.6.6 HGV/GBV-C PCR 
PCR was performed using primers specific for the 5'NCR of HGV/GBV-C. In 
brief, 5µ1 of the cDNA solution was added to a 45µ1 mastermix containing (final 
concentrations) 1X PCR digoxigenin (dig) labeling mix (200µM dATP, dCTP, 
dGTP each; 190µM dTIP, 10µM DIG-11-dUTP), 200nM of both forward and 
reverse primers, 2.6 U Expand High Fidelity polymerase and 1X PCR buffer 
[1 OmM Tris-HCI, 50mM KCI, 1.5mM MgCl2 (pH 8.3)] . Samples were subjected to 
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40 amplification cycles with three temperature settings of 94°C, 55°C and 72°C 
each for 45 seconds, followed by a 7 minute elongation period at 72°C. The 
primers and capture probe used in this study are as follows: The suitability of the 
primers for amplification South African HGV/GBV-C variants is described above. 
Sequences 
S'NCR forward 5'-CGGCCAAAAGGTGGTGGATG-3' 
5' NCR reverse 5'-AACACCTGTGGACCGTGCG-3' 
S'NCR capture probe 5'-Biotin-GGT AGCCACTATAGGTGGG-3' 
These primers and probes were provided in the Roche Molecular Biochemicals 
second generation Hepatitis G Virus Primer and Capture Probe set. 
2.6.7 Detection of amplification products 
The PCR amplification products were detected using the PCR ELISA DIG 
Detection system using a standard microtitre plate format with microtitre wells 
coated with streptavidin. The amplification products (20µ1) were diluted 1 :3 with 
denaturation solution (50mM NaOH) and incubated for 10 minutes at room 
temperature. Hybridisation buffer (440µ1) containing 75ng/ml of the biotinylated 
probe was added and 200µ1 of this solution pipetted into microtitre plate wells. 
The plates were incubated for three hours at 42°C and then washed five times. 
The provided anti-digoxigenin-peroxidase conjugate in Tris-HCI buffer (pH 7.5) 
was added to the plates, incubated at 37°C for 30 minutes and then washed five 
times to remove unbound conjugate. The enzyme substrate [1 .9mM 2,2' azino-
di(3-ethylbenzthiazoline sultanate) , diammonium salt; ABTS] in 1 OOmM 
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phosphate citrate buffer (pH 4.4)-3.2 mM H202 (as sodium perborate) was 
added and the colour developed for 30 minutes at 37°C. The absorbance was 
measured at 405nm and samples considered positive if the sample optical 
density was >3 times the negative control optical density. 
Serum samples were assessed in batches of 12 inclusive of negative and 
positive controls. The results of the RT-PCR were only accepted if the results of 
the control sera were within acceptable limits, according to the manufacturer's 
instructions. 
2.6.8 Statistical Methods 
Statistical analysis was performed using the Epi-lnfo version 6 software program 
(Center for Disease Control , Atlanta, USA) and the Statistica software program 
(Statsoft, Tulsa, USA). 
• The differences in prevalence were analysed using the Chi squared test. 
• Demographic data were tabulated and factors associated with increased risk 
of infection were assessed using discriminant analysis by stepwise method. 
• Stratified analysis was used to assess the interdependence of risk factors. 
• A p-value of <0.05 was considered to indicate statistical significance. 
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2.7 RESULTS 
2.7.1 Demographic data 
A cohort of 484 people were studied, of whom 249 were from the rural region of 
Keiskammahoek and 235 from the urban area of Cape Town. 
• The rural sample was divided into the 160 (64.3%) individuals recruited during 
the random community sampling and the 89 (35.7%) recruited from the OPD. 
All of the random community sample volunteers lived in traditional mud 
houses with no access to in-door water supply nor waterborne sewerage. 
The majority (60%) of the rural OPD sample group lived in these same 
conditions, while 30% lived in formal housing. 
• The urban group consisted of 135 individuals (57%) living in the formal 
housing sector and 100 ( 43%) individuals living in squatter settlements. 
The mean age of the entire group was 43.8 years (range 18-92). However, the 
mean ages of the rural and urban groups (47 and 40 years respectively) was 
significantly different (p=0.02). The male:female ratios of the rural and urban 
groups were 1 :1.6 and 1 :2.6 respectively. No significant differences (p>0.05) 
were shown between the urban and rural groups with regard to a history of ritual 
scarring (73.0% vs. 69.8%), major trauma (16.7% vs. 14.9%) and a history of 
hepatitis or any form of liver disease (4.0% vs. 3.8%). However, the urban group 
showed greater exposure to blood products (12.9% vs. 20.4%; p=0.02). 
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2. 7 .2 Prevalence 
One hundred and thirty of the 484 samples were HGV/GBV-C PCR positive, 
giving an overall prevalence of 26.9%. The rural and urban prevalences of 20% 
and 34% were significantly different (p=0.0005). 
2.7.2.1 Community versus OPD sampling 
The prevalence did not differ significantly in the rural group between the OPD and 
community sampling groups (20.9% and 19.4% respectively) , thereby validating 
the OPD sampling procedure for the analysis of HGV/GBV-C viraemia. No 
significance was demonstrable between the urban squatter and formal housing 
groups (p=0.17). 
2.7.3 Risk Factors 
2.7.3.1 Univariate analysis 
Univariate analysis of the questionnaire variables showed a significant 
relationship between HGV/GBV-C infection and younger age (p=0.016) and the 
use of illicit drugs (p=0.045). All positive drug histories related to marijuana 
usage and none of the recruits gave a history of intravenous drug abuse. Further 
analysis showed that this significant association with drug use was only valid for 
the urban group. Those living in squatter communities had a lower prevalence of 
HGV/GBV-C (p=0.002). However, this statistical significance was not evident 
when controlling for urban/ rural place of residence. 
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The use of pit latrines for sewerage disposal was associated with a significant 
reduction in HGV/GBV-C prevalence as compared to waterborne sewerage and 
bucket latrines (p=0.003). There were very small numbers of rural inhabitants 
with access to waterborne sewerage and equally few urban inhabitants using pit 
latrines. Thus, although the numbers prevented formal assessment, the 
association with sewerage disposal method may be a confounding factor relating 
to rural / urban life. 
Univariate analysis showed no relationship between infection and gender, water 
source, employment, a history of hepatitis or any form of liver disease, past blood 
transfusions, scarification, excessive alcohol consumption or major trauma. 
2.7.3.2 Discriminant analysis 
Discriminant analysis was performed by forward and reverse elimination, and the 
following results were obtained using forward elimination (standardised 
coefficients in brackets): drug usage (0.583), younger age (0.498), past blood 
transfusions (0.295) and female gender (0.136). The positive predictive value of 
these four factors was 59.6% and the negative predictive value was 61.6%. 
Reverse elimination analysis did not show any combination of these factors to 
have significant predictability. 
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2.8 Discussion 
This data shows the prevalence of HGV/GBV-C in adult Black South Africans to 
be extremely high and to have significant variation between urban and rural 
regions. It was expected that the South African prevalence would be higher than 
that seen in the USA and Europe, based on the published data from other 
developing countries (103,128,130,139,142). However, the mean prevalence of 
this cross-section of South African Black adults (26. 9%) is higher than any other 
published figure to date, excluding those studies assessing extremely high risk 
groups such as intravenous drug abusers. This study aimed to assess the 
carriage rate of HGV/GBV-C, and does not address the issue of past infections, 
as demonstrated by the presence of serum anti-E2. It would be expected that 
HGV/GBV-C exposure rates would be significantly higher than the figure shown 
here for carriage. 
This prevalence figure is also significantly higher than the South African figure 
generated by Casteling et al. in Johannesburg blood donors (11 .1 %) (139). 
While this may appear to be a major discrepancy, the higher prevalence of 
HGV/GBV-C in Black communities is in keeping with other data on parentally 
transmitted viruses in the transfusion service. Those attending blood transfusion 
services around the world represent a highly selected community, as a 
consequence of the stringent exclusion criteria applied to every donor (181 ). The 
same phenomenon applies in South Africa, where blood donors are 
predominantly from the middle class Caucasian population, while the data 
contained in this thesis describes the epidemiology of viral markers in extremely 
poor Black South Africans. 
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For example, the following comparison data is available from the Western 
Province Blood Transfusion Service (WPBTS) in Cape Town: 
• hepatitis B carriage is approximately 3-5% in the adult Black community 
(chapter 1 ), while first-time blood donors of the WPBTS have a prevalence of 
0.87% (personal communication with Dr. A. Bird, WPBTS). 
• As discussed in chapter 1 of this thesis, anti-HCV antibodies are detected in 
1.8% of the adult Black community of the Western Cape, while the prevalence 
is only 0.41 % in blood donors of the same province (78). 
• The HIV prevalence in 1997 amongst antenatal clinic attendees in the 
Western Cape was 6.3% (Department of Health 1997 survey) , while the 
percentage positive donations (out of 140 000) at the WPBTS in 1997 was 
0.045% (personal communication with Dr. A. Bird, WPBTS). 
The prevalence figures of this study were validated by the presence of adequate 
controls. Firstly, all batches were run in groups of 12 sera, including a positive 
and negative control. If either of these was not within the expected norms, the 
batch was repeated. Secondly, all normal precautions were taken to prevent 
DNA contamination of samples ( 182) including the use of four different rooms for 
the different stages: a) mastermix preparation; b) RNA extraction and cDNA 
synthesis; c) PCR; and d) detection. The primers and probe used in this study to 
detect HGV/GBV-C were designed according to consensus sequence data 
generated South African variants. 
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The urban and rural groups were well matched with regard to the histories 
obtained for scarification, liver disease and major trauma. However, the urban 
group comprised more women and a greater proportion of younger individuals 
with a greater percentage who had received blood transfusions. While it is 
difficult to explain the gender differences, the younger age of the urban group is 
in keeping with the movement of young adults to major urban areas in seek of 
employment. The fact that few give a history of liver disease is in keeping with 
the experience of developing countries, where almost all are exposed to HAV 
very early in life, and many exposed to HBV before the age of five (94,183). Both 
infections are most commonly subclinical when acquired early in life. 
The random community sampling was performed to validate the OPD sampling 
procedure. This showed no difference in prevalence between the two sampling 
procedures, thereby validating the OPD recruiting exercise for HGV/GBV-C. No 
significant difference was demonstrated between the urban formal housing group 
and the urban squatter communities. Squatter communities live in conditions that 
are less hygienic than their counterparts in formal housing, and do not have a 
potable water supply within the house. This comparison of the urban 
communities suggests that the life-style associated with inferior living conditions 
alone is not responsible for the increased risk of acquiring HGV/GBV-C in urban 
communities. 
Analysis of the questionnaire variables showed the use of marijuana and younger 
age to be associated with infection. None of the drug usage was intravenous. 
This is in keeping with reports from South Africa showing there to be very little 
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current abuse of such drugs (150) . The relationship with drug use was only valid 
for the urban group, suggesting that the association was probably life-style 
related, rather than the use of the drugs themselves. The association with 
younger adults acquiring the virus has been documented in other studies 
(123,184). It is important to note that the associations between infection and age 
and living in an urban city are variables that are independent of each other. 
Discriminant analysis showed a history of transfusions and female gender to be 
predictors of HGV/GBV-C positivity. However, even when combining the drug 
usage, age, transfusions and gender in this analysis, the positive predictive value 
of the combination was poor. 
The use of a pit latrine for sewerage disposal as well as living in a traditional mud 
house were associated with a lower prevalence of HGV/GBV-C using the 
univariate analysis. However, the discriminant analysis did not show these to be 
significant factors. In addition, these associations were shown to be statistically 
insignificant when controlling for urban / rural living. 
In summary, HGV/GBV-C carriage rate is high amongst adult Black South 
Africans of the Western and Eastern Cape Provinces. The prevalence rates 
differed significantly between urban and rural volunteers. Certain factors 
appeared to be associated with infection, although no combination of the 
collected variables was shown to be adequately sensitive in predicting infection. 
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CHAPTER 3 
Molecular characterisation of the 5' 
non-coding region of South African 
variants of HGV/GBV-C 
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3.1 Summary 
HGV/GBV-C has been characterised as a novel flavivirus, and to date three 
known genotypes have been characterised from West Africa, Europe/USA and 
Asia respectively. These genotype analyses have been predominantly based on 
the sequence variation of the 5'NCR of the virus. Although point mutations and 
point insertions/deletions have been documented in all flavivirus non-coding 
regions, no major deletions have been shown to date. The 5'NCR of HGV/GBV-
C appears to regulate protein translation via an internal ribosomal entry site 
(IRES). 
A 344bp PCR product of the 5'NCR of HGV/GBV-C, representing more than 60% 
of the 5'NCR was cloned, sequenced and analysed from 32 HGV/GBV-C PCR 
positive volunteers. Wild-type virus amplicons were detected in all samples. 
However, 5/32 (15.6%) also amplified another smaller PCR fragment that ranged 
between 205 and 231bp. A deletion of between 113-131bp was detected in 
isolates generating the smaller bands. Sequence analysis showed all cloned 
PCR fragments to be HGV/GBV-C-specific. RNA secondary structure analysis of 
the 5'NCR showed the deletions to be over the regions previously named 
domains II and Ill. This data suggest that nucleotides 303 to 444 may be non-
essential for 5'NCR functioning and maintenance of the IRES. 
Phylogenetic analysis demonstrated a novel fourth South African genotype, 
distinct from genotypes 1-3 with DNA distances of >0.1000. ALT and AST values 
for the wild-type and mutant samples were normal. 
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3.2 Introduction 
HGV/GBV-C variants have been shown to have genetic relatedness to previously 
described viruses such as HCV, yellow fever virus and dengue virus, all of which 
are known members of the family Flaviviridae. Thus, much of our current 
understanding of HGV/GBV-C biology is based on prior knowledge of the 
molecular features of these (104). 
The structural and genetic constituents of HGV/GBV-C and other flaviviruses is 
reviewed below. However, the literature review relating to flavivirus (and 
HGV/GBV-C) replication will be contained in the following chapter of this thesis. 
3.3 Flavivirus characteristics 
3.3.1 Physicochemical 
Not all members of the family Flaviviridae have been visualised to date. 
However, the electron microscopy data from those that have been described 
show enveloped virus particles that are 40-60 nm in diameter, spherical and 
smooth in appearance. The buoyant density of this family of viruses ranges from 
1.19 to 1.23 g/ml and virions are composed of 6% RNA, 66% protein, 9% 
carbohydrate and 17% lipid (185). 
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3.3.2 Genome and protein description 
Flaviviruses contain one single-stranded, positive sense RNA molecule. These 
genomes vary in length and are approximately 9,5-12,Skb (186). Figure 3.1 
below is descriptive of the overall genetic structure. 
Figure 3.1: 
5' NCR 
Flavivirus genome structure 
Non-structural 
proteins 
3.3.2.1 Non-coding regions 
The 3' and 5' ends of flaviviruses' single open reading frames (ORFs) are flanked 
by non-coding regions that are thought to have the capacity to regulate viral 
replication. Both of these flanking regions have a high degree of homology within 
the specific genus, and in addition have limited sequence similarities with other 
members of the family Flaviviridae outside of the genus (186). Certain members 
of the family Flaviviridae have a poly-A tail at the end of the 3'NCR, while in 
others this is absent (186-188). A type 1 cap of the S'NCR is thought to regulate 
ribosome binding in a subset of flaviviruses (see below). Flavivirus S'NCRs vary 
in length from below 100 bases to more than 400 (186,189,190). The type of 
ribosomal binding is thought to be in part determined by the length of the S'NCR. 
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3.3.2.2 Core proteins 
The gene for flavivirus core proteins is contained in the coding region adjacent to 
the 5'NCR and upstream of the envelope coding region. As a result of its 
proximity to the 5'NCR and IRES, it is the first viral protein to be translated (186). 
Core proteins are responsible for the formation of the nucleocapsid structure 
(191 ). While there are conserved RNA regions coding for both hydrophobic and 
hydrophilic amino acid domains within the core protein, there is little RNA 
homology between the different flaviviruses (191 ). 
3.3.2.3 Envelope proteins 
Flaviviruses are contained in a lipid envelope that renders them susceptible to 
destruction by organic solvents and detergents (185) . The envelope proteins are 
believed to be important for receptor binding and internalisation of the virus 
(192,193), but in addition, are the major immunological targets for neutralising 
antibodies (194). As a consequence certain flaviviruses, such as HCV, have 
developed mechanisms of escaping immune capture by way of constantly 
varying the amino acid sequence of this region through regular mutations in the 
nucleotide sequence (195,196). The envelope coding sequences are found with 
the other structural components of flaviviruses in the 5' one third of the genome. 
Comparison of corresponding envelope coding regions of different viruses within 
the family Flaviviridae show them to have areas of sequence homology 
(186,191). 
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3.3.2.4 Non-structural proteins 
The NS2, NS3, NS4, NS5A and NS5B genetic regions of flaviviruses are 
packaged in the 3' two thirds of the genome, and are known to code for the non-
structural components of the viruses. The functions of all of these components 
are not well documented. However, the NS2 protein is composed of two 
portions, A and B, both of which appear to have proteolytic activity, with the 
NS2B portion having maximal activity when complexed with the NS3 protein 
(197,198). The NS3 region codes for a non-structural protein (predicted 68-70 
kd) with at least helicase, protease and RNA triphosphatase functional capacity 
(104, 199-201 ). The NS5B protein is the largest and most conserved (- 103 kd) of 
the non-structural components and is believed to be the RNA-dependant RNA 
polymerase protein (202,203). This understanding is based on the finding of a 
highly conserved sequence motif (GOD) that is characteristic of known viral RNA-
dependant RNA polymerases. Little is known about the functions of the NS4 
proteins of flaviviruses. 
3.4 Literature review of HGV/GBV-C molecular characteristics 
3.4.1 General 
The discovery of GBV-A, GBV-B, GBV-C and HGV has resulted in a greater 
understanding of the phylogenetic relationships within the family Flaviviridae and 
its genera. Full and partial nucleotide sequences of various geographical isolates 
of these viruses have been published and are available for comparison. Initial 
sequence data suggested that the HGV/GBV-C isolates may be novel members 
of the genus Hepacivirus within the family Flaviviruses (103,104,204,205). 
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However, it is now evident that there is only approximately 30% nucleotide 
homology with HCV, thereby excluding there being such a close association 
(104,206). 
Although it is thought that the full genetic sequence of HGV/GBV-C is known, the 
vast majority of analytical work has been based on the 5'NCR sequences. Less 
is known about the sequence and functional aspects of the other components of 
HGV/GBV-C. As the work to be presented focuses on the 5'NCR of South 
African variants of HGV/GBV-C, the literature review below will focus on this 
component. 
Figure 3.2 below demonstrates the genetic structure of two flaviviruses aligned 
for the purpose of comparison. The HGV/GBV-C genome is placed above and is 
compared to that of HCV clade 1 (adapted from Leary et al. Journal of Medical 
Virology (104)) . 
Figure 3.2: 
HGV/ GBV-C GENOME 
5' NCR 3' NCR ==w----,--,----,---.--,-----, 
NS2 NS3 NS4 NS5 NS5B 
HCV GENOME 
~~~~~~~~~~-"-3'~NCR 5' NCR r----.,,,,,,, --c NS3 NS4 NS5 NS5B 
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3.4.2 The 5' non-coding region 
The most conserved regions of the HGV/GBV-C genome are the 5'- and 3'NCRs. 
The 5'NCR has a nucleotide homology of greater than 95% between isolates of 
different geographic origins (103-105,207). As a consequence, many diagnostic 
PCR assays are designed with primers specific to this region, so as to optimise 
the sensitivity of genome amplification (208). 
While there is good overall homology in the 5'NCR, this region has three variable 
regions (V1-3) where significant differences between different isolates are 
demonstrable (206). The nucleotide substitutions are in the most, consistent 
amongst isolates from similar geographic regions and genotypes (105). As 
described below, the substitutions in this region are mostly covariant, thereby 
allowing for maintenance of RNA secondary structure (209). Single base 
insertions and deletions have been demonstrated in the 5'NCR of all flaviviruses. 
However, no major deletions have been shown to date in the 5'NCR of any 
HGV/GBV-C, HCV, GBV-8 or GBV-A isolate. 
3.4.2.1 5'NCR boundaries 
The extreme 5' RNA sequence of the HGV/GBV-C 5'NCR was described 
subsequent to the initial discoveries of HGV and GBV-C, using a modified RACE 
technique (rapid amplification of cDNA ends) (206). In describing this region , the 
investigators have found evidence suggestive of an RNA hairpin loop at the 
extreme 5' end of the RNA that is similar to that seen in the models of HCV 
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5'NCR structure (206,210). It is possible that this hairpin loop is important in self-
priming of the RNA during RNA replication (206,210). 
There remains a level of uncertainty with regard to the position of the 3' end of 
this NCR, as the 5'NCR of HGV/GBV-C has multiple potential start codons that 
are in-frame with the downstream open reading frame, available for translation 
initiation (209). The initial uncertainty was in part due to an unsuccessful search 
for the viral core protein coding sequence. As discussed below, there is no 
evidence supporting the presence of a typical core protein sequencing region for 
both HGV/GBV-C and GBV-A, although GBV-8 has sequence typical of a core 
region . Hsieh et al. (1997) suggested a 465 nucleotide long non-coding region 
for HGV/GBV-C (206). However, subsequent evidence has suggested that the 
start codon for the HGV/GBV-C open reading frame is 93 nucleotides further 
downstream (209,211). 
3.4.2.2 Regulation by the 5'NCR 
The 5'NCRs of flaviviruses are thought to regulate translation of their respective 
single downstream open reading frames (205,210). The open reading frame 
codes for both functional and structural proteins together. These proteins are 
cleaved later and modified post-translationally. 
The mode by which the 5'NCRs of different flaviviruses regulate translation 
appears to vary. 
• The flaviviruses with shorter 5'NCRs (e.g. dengue and yellow fever) are 
thought to use an eukaryotic ribosome scanning mechanism. In this model of 
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ribosome activity, the ribosome binds at the 5' cap structure of the RNA and 
scans the region until the functional (not necessarily the first) AUG codon. At 
this point, the translation of the downstream open reading frame begins (212). 
• The flaviviruses with longer 5'NCRs are thought to initiate translation in a 
similar fashion to that employed by picornaviruses, where the ribosome binds 
to an internal ribosomal entry site (or landing pad) created by the secondary 
structure of the RNA (213). HGV/GBV-C has a very long 5'NCR and initial 
experimental evidence suggests that it uses this second strategy to regulate 
translation (205). 
3.4.2.3 5'NCR secondary structure 
The secondary (and tertiary) structure of the 3' terminal portion of the 5'NCR 
RNA, as well as the initial portion of the coding region , appears important for 
ribosome binding in flaviviruses (205,209). Thus mutations / alterations to this 
RNA sequence may change the structure to varying degrees. The necessity to 
maintain the structure of the ribosome landing pad is almost certainly the reason 
for the conserved nature of the entire 5'NCR. Although the ribosome binding site 
is relatively close to the start codon (210) , the entire non-coding region is thought 
to act as a scaffold for the maintenance of the terminal portion structure. It is 
thus not surprising that Fukushi et al. (1994) have documented that a complete 
5'NCR of HCV is required for maintenance of the internal ribosomal entry site 
(214) . The highly conserved nature of both the HGV/GBV-C and HCV S'NCRs 
suggests the same may hold for HGV/GBV-C protein translation. 
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Different groups have attempted to predict the RNA secondary structure of the 
HGV/GBV-C 5'NCR of isolates falling into the genotypes 1 and 2 (205,209). 
These proposed structures have similarities with that proposed for the 5'NCR of 
GBV-A (205) and show relatively little variation between isolates. Maintenance of 
the RNA secondary structure has been shown to be important. Therefore it is no 
surprise that when comparing these proposed structures with the nucleotide 
sequence, the majority of nucleotide substitutions are covariant substitutions 
(209). Thus, although there is diversity over the three variable regions of 
HGV/GBV-C, the RNA structure remains relatively constant. 
It is difficult to say with certainty that the RNA structure proposed in these 
mathematical analyses is a fair indication of the in-vivo structure, as inevitably the 
RNA form is not static, and is dependant on energy levels and the biochemical 
cellular milieu (215). Accurate determination of the RNA structure is also 
dependant on having sufficient of the upstream RNA sequence in the analysis, so 
as to adequately represent the formation of the entire region (215). The different 
energy levels and cellular environments will inevitably have an effect on the 
structure of this region and in doing so, either allow replication of the virus or not. 
Conventional software programs predict the secondary, but not tertiary structure 
of RNA molecules. Thus, the results are probably an over simplification of the 
complexities of RNA structure. 
3.4.3 Core 
The genetic relatedness of HGV/GBV-C and HCV is evident from the diagram 
above (Figure 3.2) , with the exception of the coding segment for the core protein 
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that is absent in HGV/GBV-C (103,205,207,216). Analysis of the entire genome 
of HGV/GBV-C (and GBV-A) has not demonstrated any RNA region with 
sequence suggestive of a nucleocapsid protein. This is unexpected, as these are 
the only two flaviviruses that have been described without a core coding 
sequence (101 ,205). The possible reason for its absence and the functional 
implications thereof remain unexplained. It has been speculated that HGV/GBV-
C may have a core protein that is very different from those previously described 
before for other flaviviruses, or that it may be reliant on either a cellular protein or 
the core protein of another virus to act as a surrogate core protein (209). 
3.4.4 Envelope 
HGV/GBV-C has two coding regions for envelope proteins. The E1 gene of 
HGV/GBV-C is shorter than that of the E2 coding region and has greater 
homology with the corresponding E1 region of HCV than the E2 region (104). 
The E1 and E2 coding regions are located just downstream of the S'NCR and 
unlike envelope proteins of other flaviviruses such as HCV, show a high degree 
of RNA homology between different HGV/GBV-C isolates (217-219). HCV has a 
hypervariable region in this area, and this is thought to facilitate escape from 
immune capture, as described above. 
The lack of nucleotide variability in the HGV/GBV-C E1 and E2 genes is reflected 
in great homology in envelope amino acid sequences. As these envelope 
proteins are targeted by the immune system for viral clearance (217), this offers 
the virus no mechanism of temporary escape from immune capture. As a 
consequence, while antibodies to HCV envelope proteins are mostly a marker of 
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chronic infection, antibodies to the E2 protein of HGV/GBV-C are invariably 
associated with viral clearance (130). Thus, as described in chapter 2, the 
presence of viral RNA and antibodies are almost mutually exclusive. 
3.4.5 Non-structural regions 
The genes coding for the non-structural components of HGV/GBV-C are found in 
the two-thirds of the genome downstream of the E2 region (104). Although there 
is a degree of homology with HGV/GBV-C and other flaviviruses, the complete 
functions of all of the components remains unclear. 
The similarity of the NS2 RNA segment of HGV/GBV-C to other flaviviruses 
suggests that this region codes for a viral protease. However, full clarity with 
regard to it's function in HGV/GBV-C biology remains unclear. The NS3 region 
has the greatest homology with the equivalent HCV genome segment and 
probably codes for both a protease and a helicase protein (104). 
The functional aspects of the NS4 and NS5A segments remain undescribed. 
Analysis of NS5A sequences generated from central African HGV/GBV-C 
isolates show a 36 nucleotide insertion (220). The NS58 region is thought to 
code for the RNA-dependant RNA polymerase protein (104). This enzyme is 
central to the production of RNA replicative intermediaries during viral replication. 
The negative strand RNA is then used by the same enzyme for production of 
further virion RNA (see chapter 4 for further description). 
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3.4.6 The 3' non-coding region 
Comparatively little data is available on the genetic variability of the 3'NCR of 
HGV/GBV-C, although the available data does suggest that it is highly conserved 
(104,221). Although initially thought to be only approximately 60 bases in length 
(104), it was later found to be in excess of 310 bases (211 ,221). HGV/GBV-C 
has neither a poly-A nor a poly-U tail configuration (104,211 ,221). The same is 
seen in GBV-A, once again showing its closely shared origins with HGV/GBV-C. 
3.4.7 Genetic relatedness of different HGV/GBV-C isolates 
3.4. 7 .1 Phylogenetic analysis 
Phylogenetic analyses of GBV-A, GBV-8, GBV-C, HGV and HCV have shown 
the following : 
• HGV and GBV-C are variants of the same virus (thus HGV/GBV-C) that form 
a distinct group separate from HCV; and 
• HGV/GBV-C is most closely related to (but distinct from) GBV-A. 
These analyses demonstrate the presence of three genotypes which show 
consistent geographical clustering with West Africa, USNEurope and Asia. 
These have been named genotypes 1, 2 and 3 respectively 
(105,207,211 ,221,222). The genetic variability of genotypes 1 and 2 has led to 
certain investigators subgrouping each of these into genotypes 1NB and 2NB 
respectively. 
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The most consistent phylogenetic analysis results for HGV/GBV-C are reported 
to be those generated from the sequence of either the complete genome or the 
5'NCR (222,223). Phylogenetic analysis of shorter HGV/GBV-C fragments from 
the E2, NS3 or NS5B region produce divisions that do not cluster according to 
geographic origins (216,223). 
3.4.7.2 DNA distance 
DNA distance analysis allows another measurement of variation in the genome 
and more specifically the evolutionary distance between the genotypes 
described. Evolutionary differences have been described for the HGV/GBV-C 
genotypes 1-3, using 5'NCR sequence (207). Table 3.1 below describes their 
findings (modified from AS. Muerhoff; Journal of Hepatology, 1996, Vol 25, page 
382). It is evident that the DNA distance within each genotype is significantly less 
that that seen between genotypes. 
Table 3.1: DNA distances values for HGV/GBV-C genotypes 1-3. 
HGV/G8V-C 1A 18 2A 28 3 
genotype 
1A 0.056 0.092 0.133 0.123 0.115 
18 0.053 0.137 0.127 0.128 
2A 0.039 0.065 0.101 
28 0.034 0.092 
3 0.012 
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3.5 Study motivation 
No isolates from Southern Africa have been included to date in the studies 
characterising the 5'NCR region of HGV/GBV-C. 
3.6 Aim 
Thus, this study aimed to investigate the molecular characteristics of the 5'NCR 
of South African variants of HGV/GBV-C, and compare them to those previously 
described. 
3. 7 Materials and methods 
3.7.1 Specimens: 
3.7.1.1 Sample number and profile 
Thirty two HGV/GBV-C RNA positive serum specimens were obtained from 
volunteers recruited in the Western and Eastern Cape Provinces of South Africa. 
The serum specimens were taken from those who were HGV/GBV-C RT-PCR 
positive, as described in chapter 2 of this thesis. These included individuals 
residing in both rural villages and the metropolitan urban area of Cape Town. 
3.7.1.2 Control samples 
Positive and negative control sera were supplied by Roche Molecular 
Biochemicals, Germany. 
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3. 7 .2 RNA extraction 
RNA was extracted from 200 µI serum using Total RNA Isolation Reagent 
(Advanced Biotechnologies Ltd ., London, UK), as described in chapter 2 of this 
thesis. 
3.7.3 cDNA synthesis 
A cDNA synthesis step was performed using MMLV reverse transcriptase and 
random hexamer primers, as described in chapter 2 of this thesis. 
3.7.4 HGV/GBV-C PCR and Detection 
3. 7.4.1 General parameters 
A nested PCR was performed on all 32 samples using the primers described 
below (224). Five microlitres of the above cDNA solution (or outer product) was 
added to a 45µ1 mastermix containing (final concentrations) 200µM dATP, dCTP, 
dGTP and dTTP each, 2.6 U Expand High Fidelity polymerase and 1X PCR 
buffer [1 OmM Tris-HCI , 50mM KCI , 1.5mM MgCl2 (pH 8.3)] (all Roche Molecular 
Biochemicals, Germany) and the relevant forward and reverse primers. Samples 
were subjected to 35 amplification cycles as described in chapter 2 of this thesis. 
3.7.4.2 Primers 
sense 5' -AGGTGGTGGATGGGTGAT-3' 
anti sense 5'-TGCCACCCGCCCTCACCCGAA-3' 
nested sense 5' -TGGT AGGTCGT AAA TCCCGGT-3' 
nested antisense 5' -GGAGCTGGGTGGCCCCATGCAT-3' 
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3.7.4.3 PCR amplicon size and region 
The final PCR product (inclusive of nested primers) spanned a predicted 344 
base pair (bp) region of the 5'NCR from base 139 to 483 (numbering according to 
that of accession number U76893) (206) . 
3.7.4.4 Visualisation 
The PCR products were separated by electrophoresis in 2% agarose gel and 
visualised under ultra-violet light using ethidium bromide staining. 
3. 7 .5 Southern Blot 
The PCR fragments were confirmed as being HGV/GBV-C specific by Southern 
blot hybridization analysis as follows. 
3.7.5.1 Transfer of PCR products 
The PCR products in the agarose gel were denatured for 30 minutes in a 0.5M 
NaOH 1.5 M NaCl solution and subsequently neutralised for 40 minutes in 20 mM 
NaOH 1 M ammonium acetate. The PCR products were transferred from the 
agarose gel to a Hybond-N nylon membrane (Amersham, UK) by capillary 
method, and cross-linked to the nylon membrane by applying 2400 watts of 
ultraviolet light. 
3.7.5.2 Prehybridization 
The nylon membrane was placed in the rotating tube of a hybridisation oven for 4 
hours at 42°C in a 40 millilitre solution containing 6X standard sodium citrate 
(SSC), 0.1 % blocking reagent (Roche Molecular Biochemicals, Germany) and 
1 % sodium dodecyl sulphate (SOS) (see appendix for reagents) . 
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3.7.5.3 Probe and probing conditions 
A denatured digoxigenin-labeled HGV/GBV-C PCR product was used as a probe 
for confirmation that the amplicons visualised on the gel were HGV/GBV-C 
sequence specific. This PCR product was generated as described in the 
previous chapter of this thesis from an HGV/GBV-C positive sample (ZAN22}, 
and spanned 186bp of the 5'NCR of HGV/GBV-C. 
The cDNA probe was denatured by boiling for 5 minutes followed by immediate 
freezing on dry ice. The probe was then added to the prehybridisation solution 
and incubated overnight at 42°C. 
3.7.5.4 Stringency washes 
The nylon membrane was removed from the hybridisation solution and washed 
twice at 42°C for 15 minutes in a solution containing 2 X SSC 0.1 % SOS. This 
was followed by a second round of stringency washes with identical temperature 
and time parameters using a 0.1X SSC 0.1 % SOS solution. Finally, the 
membrane was washed for 5 minutes at room temperature in washing buffer 
(buffer 1 containing 0.3% Tween-20) (see appendix for buffer 1 ). 
3.7.5.5 Detection system 
All detection steps below were performed at room temperature. The membrane 
was incubated in 1 % blocking (see appendix) buffer for 30 minutes, followed by a 
further 30 minutes incubation after the addition of anti-digoxigenin Fab fragments 
( 1: 10 000 dilution) (Roche Molecular Biochemicals, Germany). The membrane 
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was washed twice in washing buffer for 15 minutes and equilibrated for 2 minutes 
in buffer 3 (see appendix) . A 1 :100 dilution of CDP-Star (Roche Molecular 
Biochemicals, Germany) in buffer 3 was added and incubated for 5 minutes. The 
excess liquid was removed and the membrane sealed in a plastic covering. The 
membrane was exposed to medical X-ray film (Agfa, Belgium) for 1 minute, 
followed by processing of the film by conventional methodologies. 
3.7.6 Cloning 
PCR products were cloned using the pCR-Script Amp SK+ cloning kit 
(Stratagene, La Jolla, CA) as suggested by the manufacturer. Transformed 
Epicurian coli® XL 1-Blue cells were grown overnight on agarose 2 X yeast-
tryptone broth containing 1 OOµM ampicillin, 1 OOµM 5-bromo-4-chloro-3-indoyl-~-
D-galactopyranoside (X-gal) and 0.5µM isopropyl-1-thiol-~-D-galactopyranoside 
(IPTG) (see appendix). Bacterial colonies were selected according to blue/ white 
differentiation and grown for 16 hours in 100ml 2 X yeast-tryptone broth 
containing 1 OOµM ampicillin. 
Plasmid DNA was extracted (Nucleobond, Macherey-Nagel GmbH, Duren, 
Switzerland) and subjected to restriction enzyme digestion with Pvu II (Roche 
Molecular Biochemicals, Germany) to confirm the inclusion of the desired cDNA 
fragment size. Digested plasmids were separated in 2% agarose gels containing 




Eight of the samples containing the predicted HGV/GBV-C fragment size were 
sequenced. In addition, a clone from all five of the samples shown to have a 
smaller inserted fragment was sequenced. 
3.7.7.2 Sequencing method 
Sequencing was performed in both the forward and reverse directions using the 
Pharmacia™ ALF express® automated sequencer (AM version 3.01 , Pharmacia 
Biotech) by Ms. D. James of the University of Cape Town Department of 
Microbiology. Any sequence discrepancies were resolved by repeat sequencing. 
3.7.8 Supplementary testing of mutant samples 
Serum samples found to contain a virus with the deletion (see results) were re-
evaluated in the following manner for confirmation of this finding. 
3.7.8.1 Repeat testing 
The complete RT-PCR process was repeated using the same methodology. 
3.7.8.2 Heat denaturation 
The RNA suspensions were heat denatured at 95°C for five minutes followed by 
immediate cooling on ice, prior to reverse transcription so as to reduce the 
secondary structure of the RNA region during reverse transcription. 
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3.7.8.3 Supplementary nested PCR 
Samples that generated only a mutant virus amplicon with the above protocol 
were subjected to a separate supplementary nested PCR. This supplementary 
PCR assay used the same "outer" reaction described above. However, the 
nested PCR was designed with an antisense primer internal to the deleted 
region, thereby preventing amplification of the mutant and excluding the 
possibility that the mutant virus was "out-competing" the wild type virus in the 
PCR reaction. The following antisense primer was used in the nested reaction: 
5'-AGAGAGACATTGAAGGGCGACG-3'. 
3.7.9 Sequence Analysis 
3.7.9.1 Numbering system and comparison sequences 
The nucleotide numbering used in the analysis below was derived from either: 
A) the position within the PCR product or; 
B) according to the numbering system of accession number U76893 (206). 
Sequences that were used for comparison with the South African samples were 
representative of all three genotypes previously described: (accession numbers) 
U59518-21, U59529-33, U59543-53, U76893, 087251 , 087708-14 and 090601 . 
The original HGV isolate, PNF2161 (U44402) and the GBV-C isolate (U36330) 
were also included in the analysis. 
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3.7.9.2 Sequence alignment and phylogenetic analysis 
Alignment of sequences was performed using ClustalW version 1.6 (European 
Molecular Biology Laboratory, Heidelberg, Germany) with final manual alignment 
by eye. 
Phylogenetic analysis was performed with ClustalW and Treecon for Windows 
version 1.1 (Antwerpen, Belgium), using the neighbour joining method and 
Kimura algorithm, with gaps included. Phylogenetic trees were visualised using 
the Treeview computer program version 1.2 (IBLS, University of Glasgow). 
3. 7.9.3 Bootstrap analysis 
ClustalW was used to assess the statistical reliability of the tree using the 
Felsenstein bootstrap method based on 100 repetitions. 
3.7.9.4 Inclusion of mutant samples in analysis 
The tree and bootstrap values were initially generated comparing only the wild-
type South African variants with the other published sequences. Deletion isolates 
were then included individually (using the same methodology) with the deletion 
gap considered to be one mutational event. 
3.7.9.5 DNA distance analysis 
Intra- and inter-genotype DNA distance values were generated with ClustalW. 
100 
3.7.10 RNA secondary structure analysis 
The predicted RNA secondary structure was generated using the MFold 
computer program (215). The Mfold program uses the energy rules, as 




3. 7 .11 Biochemistry 
Serum ALT and AST were measured (by the Chemical Pathology Department 
staff of the University of Cape Town) using the Roche Diagnostics 747 serum 
analyser. 
3.8 Results 
3.8.1 Initial analysis 
3.8.1.1 Wild type 
Twenty seven of the 32 samples (84.3%) amplified the predicted 344bp PCR 
fragment (Figure 3.3). 
3.8.1.2 Mutant 
Of the remaining five samples, three (9.4%) generated smaller PCR fragments of 
214, 215 and 231 bp respectively (ZAF87, ZAN11 and ZASq13). The last two 
samples (6.3%) (ZAF3 and ZAF115) each generated two PCR bands: one of the 
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predicted fragment size of 344bp and another of 205 and a 211 bp respectively 
(Figure 3.3). 
The samples consistently amplified the same size amplicons, and manipulating 
the reverse transcription conditions as described in 3.7.8 above did not alter this. 
Figure 3.3: 
This photograph is of a representative agarose gel electrophoresis pattern for 
serum samples containing wild-type virus, mutant virus and both. Lanes I to 10 
contain the following in order: molecular weight marker VI (Roche Molecular 
Biochemicals, Germany), negative control, positive control, and samples ZAK28, 
ZAN?, ZAN11, ZAN22, ZASq13, ZAK12 and ZAF3. 
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3.8.2 Southern blot 
Southern blot analysis (after nested PCR) showed that both the predicted 344bp 
PCR fragments as well as the smaller fragments were HGV/GBV-C specific. 
Samples ZAF87, ZAN11 and ZASq13 showed no evidence of the wild-type cDNA 
fragments by Southern blot. Figure 3.4 below demonstrates the Southern blot 
findings using the same samples as shown in Figure 3.3 (scanned with a black 
and white filter) . 
Figure 3.4: Southern blot pattern demonstrating specificity of PCR amplicons. 
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3.8.3 Cloned fragments 
Restriction fragment analysis of clones confirmed the sizes of the inserted PCR 
fragments. 
3.8.3.1 Samples with single PCR bands 
Many clones from each sample were analysed, and all clones from the samples 
with a single PCR band contained only one cDNA insert size (whether the 
predicted size or smaller) . 
3.8.3.2 Samples with two PCR bands 
Different clones from samples ZAF3 and ZAF115 contained either the 344bp or 
the smaller fragments. 
3.8.4 Supplementary analysis of mutant samples 
Wild-type virus was not detected in samples ZAF87, ZAN11 and ZASq13 using 
the above amplification protocol. However, wild type virus was detected when 
using the supplementary PCR with the primer internal to the deleted region. 
3.8.5 Sequence analysis 
3.8.5.1 Wild-type 
Sequence analysis of the cDNA clones showed all to be HGV/GBV-C-specific. 
The sequence alignment of eight wild type HGV/GBV-C isolates, including the 
wild type (wt) sequence of ZAF3 and ZAF115, is shown in Figure 3.SA below. 
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3.8.5.2 Mutant type 
Deletant sequences from clones ZAN11 , ZASq13 and ZASq87, as well as those 
clones containing the smaller fragment of ZAF3 and ZAF115 (designated 
ZAF3mut and ZAF115mut) are shown in Figure 3.58. All deletions were over the 
same nucleotide region , with minor variation. 
3.8.5.3 Variable regions 
The degree of sequence heterogeneity in variable regions 2 and 3 (V2 and V3) is 
significantly higher than that seen in the other 5'NCR segments of the South 
African isolates. The variable regions account for only 20% of the length of the 
amplicons (excluding primers). However, 52% of the point mutations are in V1 
and V2. Thus in variable regions 2 and 3, there is a point mutation on average 
every 1.8 bases, compared to a point mutation every 7.4 bases outside these 
regions. 
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Consens TGCCCTTCCCGGGGGAGCGG GAAATGCATGGGGCCACCCA GCTCC 
# One base removed from numbering to accommodate shift at position 308. 
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3.8.5.4 Deleted regions 
Overview: 
Analysis of the sequences show the deletions to end almost uniformly at base 
305 or 306 (of the predicted PCR product). However, each of the deletions starts 
at a different position over a span of 28 bases. The deleted sequence is over a 
region of the 5'NCR that is initially well conserved, and then terminates after 
variable region Ill (206). 
Specific deletions: 
Thus, using the numbering system of accession number U76893 (206), the 
deletion in clone ZASq13 was from base pair position 333 to 443. The deletions 
in clone ZAN11, ZAF87, ZAF3 and ZAF115 all terminated at base position 444, 
but started at nucleotide 314, 313, 303 and 310 respectively (Figure 3.58). 
3.8.5.5 Phylogenetic analysis 
Tree configuration: 
Phylogenetic analysis, as shown by the unrooted tree below (Figure 3.6), showed 
9/13 (69%) of the South African isolates to cluster into a separate, distinct group 
when compared to isolates from West Africa, Asia and Europe/USA. The South 
African cluster was not an artifact induced by the deletants, as the same 
phylogenetic relationships were present when the analysis was performed 
without the inclusion of the deletant isolates. The tree is consistent with previous 
phylogenetic analyses demonstrating geographic clustering of genotypes 1-3 with 
West Africa, Europe/USA and Asia respectively (105,207). 
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The statistical reliability of the tree was confirmed by bootstrap analysis. Figure 
3.6 demonstrates the bootstrap values (in italics) where that figure exceeded a 
score of 80. The divisions into genotypes 2 and 3 remain as previously 
published, as does genotype 1, where the sub-division within genotype 1 A and 
1 B is demonstrable. The South African group also has a possible subdivision 
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within the new cluster, with samples ZAK12, ZAN?, ZAF87 and ZAN13 
distinguishable from others in the grouping. 
3.8.5.6 DNA distance assessment 
The mean DNA distance values within and between the three known genotypes 
and the SA cluster are shown in Table 3.2, as a mean and standard deviations (in 
brackets). The DNA distances between the South African group and the other 
genotypes were all >0.1000; i.e. as large as that previously described between 
genotypes 1-3 (207), thus demonstrating the presence of a novel fourth genotype 
in South Africa. 
Table 3.2: DNA distance values for HGV/GBV-C genotypes. 
n 1 2 3 ZA 
1 12 0.0677 0.1200 0.1109 0.1126 
0.0349 0.0101 0.0181 0.0217 
2 10 0.05139 0.0941 0.1055 
0.0137 0.0122 0.0113 
3 10 0.0274 0.1113 
0.0088 0.0089 
ZA 9 0.0543 
(0.0210) 
Samples falling outside of South African cluster: 
Four SA isolates did not fall within the new SA clustering (Figure 3.6). Sample 
ZAK28 was closely associated with the HGV-like isolates (genotype 2), while the 
samples ZASq13, ZAF115wt and ZAF115mut were related to the GBV-C-like 
variants, previously described in West Africa (genotype 1 ). 
109 
Position of mutants: 
Three of the deletion isolates (ZAN11 , ZAF3 and ZAF87), clustered with the new 
South African group, while ZASq13 and ZAF115mut fell into genotype 1. The 
different viruses (wild-type and deletion) contained in the samples ZAF3 and 
ZAF115 were shown to be very closely associated phylogenetically, suggesting 
that the deletion isolates may have been formed within the host (see Figure 3.6). 
3.8.6 RNA secondary structure 
RNA secondary structure analysis (Figure 3. 7) showed the predicted 5'NCR 
region of the wild type isolates to have a structure comparable to that previously 
described (209). 
3.8.6.1 Deleted region 
The deletion involved two major stem loop structures (domains II and Ill) and an 
additional smaller upstream loop structure. The start positions of the deletions 
are marked S1-5, while the termination positions are marked T1 and T2 in Figure 
3.7. Comparative analysis of the nucleotide sequence in Figure 3.5A and the 
predicted RNA structure in Figure 3. 7 showed 85% of the nucleotide changes in 
the variable regions (II and Ill) to be covariant substitutions, thus allowing for the 
maintenance of the stem loop structure. 
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Figure 3. 7: Predicted RNA secondary structure of the S'NCR showing overall 
structure and deleted regions. 
3.8. 7 Biochemistry 
Sample 
ZAN22 
ALT and AST values for all 32 wild-type and mutant HGV/GBV-C samples were 
within the normal limits. No differences were demonstrable between the samples 
within the genotype 4 and the mutant samples. 
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3.9 DISCUSSION 
The 5'NCR of flaviviruses has been extensively investigated because of their 
putative role in regulation of translation. The analysis of this data shows certain 
features not described before for HGV/GBV-C and the family Flaviviridae. 
3.9.1 Phylogenetic and evolutionary distance analysis 
Previous phylogenetic analyses of HGV/GBV-C have shown the presence of only 
three genotypes (105,211,221,222). The data from this study is supportive of 
those analyses, but in addition describes a fourth genotype that predominates in 
Southern Africa. It is important to note that only West African isolates were 
included in the published studies to date and none were from South Africa. 
The DNA distance analysis shows the evolutionary distance between the South 
African cluster and the other genotypes to be as great as those previously 
demonstrated between genotypes 1-3, i.e. >0.1000. The data suggests that 
South African genotype is a less heterogeneous group than genotype 1, but 
equally heterogeneous than genotype 2. As discussed in the literature review, 
both genotypes 1 and 2 have been subdivided by investigators into two 
subdivisions, A and B. Figure 3.6 above gives an early indication that the South 
African genotype may also be subdivisible. However, further isolates will be 
required to confirm or refute this. The geographic origin of an organism is often 
presumed to be that area where maximum genetic diversity occurs. The data 
above showing additional HGV/GBV-C heterogeneity in Africa supports the 
hypothesis that HGV/GBV-C may originate in this continent (220) . 
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It is not surprising that four of the South African isolates are phylogenetically 
related to genotypes that predominate outside of the region , as South Africa is a 
heterogeneous society with strong trade and cultural roots in both Africa and 
Europe/USA, with substantial movement of individuals between these regions. 
HCV clade 5 predominates in Southern Africa while it is not common elsewhere 
(85) . This data provides the first evidence to suggest the same for HGV/GBV-C. 
The finding that the deletion isolates do not form a separate cluster is noteworthy 
and suggestive of the capacity of multiple genotypes to form this mutation. The 
selective advantage (if any) of this mutant genetic form has yet to be elucidated. 
Individuals containing both the wild type and mutants were not limited to 
genotype 4. For ZAF3 and ZAF115, the closeness of the two isolates in each of 
these individuals is suggestive of the deletion being generated after infection with 
a single strain, and not being due to separate infections. It remains unclear 
whether the mutant has the capacity to produce infectious particles, and thus 
whether individuals can be infected with the deletion isolate alone. 
3.9.2 Sequence analysis 
3.9.2.1 Wild-type sequence 
The primers used to amplify HGV/GBV-C sequence were designed for the 
conserved region between variable regions 1 and 2 (V1 and V2) and the 
conserved region downstream of V3. Thus the clones contain sequence over two 
of the three S'NCR variable regions (V2 and V3) previously described (206) . The 
South African sequence data show similar patterns to those previously described, 
with a high degree of heterogeneity in V2 and V3. The variable regions account 
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for only 20% of the length of the amplicons (excluding primers). However, 52% 
of the point mutations are over the same region. These variations in V2 and V3 
do not allow discrimination between the samples from the Western and Eastern 
Cape Provinces, and this almost certainly reflects the very significant movement 
of people between these two provinces. 
3.9.2.2 Mutant isolates 
Minor variation in the S'NCRs is well established (105,206,207). However, this 
study documents the first major deletion found in the S'NCR of HGV/GBV-C 
isolates. No such deletion has been demonstrated to date in any member of the 
family Flaviviridae. 
The deleted sequence in the five isolates shows variation in the position where it 
begins, and to a lesser extent the point where consensus sequence is re-started . 
The five samples show the initiation position of the deletion start point to span a 
region of 28 bases. The end point of the five deletions is more constant, with all 
but one ending at the same point and the last only one base away. The data 
suggest that the bases between 303 and 444 of the S'NCR are non-essential for 
a functionally competent internal ribosomal entry site. 
It was not possible to detect the mutant virus in the absence of the wild-type. The 
search for small quantities of the wild type virus in ZAF87, ZAN11 and ZASq13 
was performed using three methods, of which only one was successful. In the 
first instance, a nested PCR assay followed by Southern blot hybridization was 
unable to detect wild type RNA transcripts. Secondly, purifying many clones from 
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each of these samples and performing restriction fragment length analysis 
revealed none of the predicted full length cDNA fragments. The wild-type 
transcripts were only detected in samples ZAF87, ZAN11 and ZASq13 when 
using a primer internal to the deletion. This is suggestive that the mutant cDNA 
"out-competed" the wild-type cDNA during the PCR process. This may have 
been due to a vast difference in RNA titre and/or a more efficient amplification 
due to size differences. 
The possibility that these deletions are due to reverse transcription or PCR errors 
exists. However, efforts were made to exclude any possible errors in these 
processes. All serum samples showed consistent results with multiple repeat 
testing using the standard protocol. Heat denaturation of the RNA immediately 
prior to RT did not alter this. In addition, changing the PCR denaturation and 
annealing conditions gave identical results. Had the deletion findings been due 
to a RT artifact, it would have been expected that over 15% of the samples would 
have shown these deletions and that samples would have given different results 
after changing the test parameters. The variation in the deletion length also 
suggests a more dynamic biological role involved that requires further 
investigation. 
3.9.3 RNA secondary structure and IRES 
The fact that these HGV/GBV-C isolates are able to accommodate such a large 
deletion in the S'NCR distinguishes HGV/GBV-C from HCV, as HCV requires a 
complete S'NCR to remain translation efficient (214). It has been suggested that 
the HGV/GBV-C S'NCR has weak IRES activity (205) . IRES regions have been 
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shown to be within a short distance of the ATG start codon (210). Thus this data 
suggests that the IRES is well downstream of HGV/GBV-C base 444, so as to 
preserve this structure. 
There is significant variability in specific regions of the 5'NCR. However, 
comparison of the sequence data and the predicted secondary structure of the 
RNA shows approximately 85% of the variation to comprise covariant 
substitutions, thus facilitating preservation of the RNA secondary structure. 
The presence of these deletions over domains II and Ill supports the proposal 
that the 5'NCR is longer than the 465 bases initially proposed (206,209,211). 
The South African deletions remove domains II and Ill and end only 25 bases 
upstream of the proposed ATG codon at base 465, thereby almost certainly 
altering the RNA secondary structure of the region. However, if the true start 
position is 93 bases further (209,211), the preserved region downstream of the 
deletion would be extended to 118 bases and thereby possibly keep domains IV 
and V sufficiently unaltered to preserve IRES function. It must be noted that the 
South African nucleotide sequence used in this analysis did not include the 
extreme 5' portion of the 5'NCR. As this region may be an important component 
influencing the RNA structure, there may be differences demonstrated when 
included in the analysis. 
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3.9.4 Implications for primer design 
The deletion occurs over an area initially proposed as being suitable for primer 
design (226) . Thus, it is possible that groups using primers over this region have 
missed deletion isolates. 
3.9.5 Biochemistry 
Almost all evidence to date suggests that HGV/GBV-C neither replicates in the 
liver nor causes hepatitis (see next chapter) . All serum samples investigated in 
this study had ALT and AST levels within the normal ranges, suggesting that both 








The tissue tropism of HGV/GBV-C has been investigated in a limited manner by a 
number of investigators, and no conclusive site of replication has been found. 
Recently, a more extensive investigation of the sites of replication of HGV/GBV-C 
was undertaken in selected organs removed from immunocompromised patients 
who had died of AIDS (n=4) or cirrhosis (n=2). The studies suggested that the 
spleen and bone marrow were sites of HGV/GBV-C replication. However, there 
is no data to date in normal subjects nor in an extensive set of human organs. 
Therefore, this study investigated the sites of HGV/GBV-C replication in serum 
and twenty-three different organs collected during post-mortem examination of 
apparently healthy individuals (n=45) who died accidental deaths, a subset of 
whom had evidence of HGV/GBV-C infection. The four HGV/GBV-C PCR 
positive cadavers that were investigated for replication sites were anti-HIV and 
anti-HGV negative. Tissues were carefully collected to prevent cross 
contamination. A strand-specific RT-PCR assay for the detection of either 
HGV/GBV-C positive strand RNA (virion) or negative strand RNA (replicative 
intermediary) was employed. Strand specificity of the RT-PCR assay was 
assessed with synthetic positive-and negative strand HGV/GBV-C RNA 
generated from a plasmid, using T7 and T3 RNA polymerases. 
Spleen and bone marrow biopsies were found to be positive for both negative-
and positive strand HGV/GBV-C RNA in all four cadavers. In addition, one 
cadaver was positive for both RNA strands in the kidney, and another positive for 
both strands in the liver. No negative strand RNA was detected in the following: 
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brain, muscle, heart, thyroid , salivary gland, tonsil , lung, lymph nodes, gall 
bladder, pancreas, oesophagus, stomach, small bowel , large bowel , adrenal 
gland, gonad, aorta, skin and cartilage. 
This study concludes that HGV/GBV-C is a lymphotropic virus that repl icates 
primarily in the spleen and bone marrow. 
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4.2 Introduction to flavivirus replication 
HGV/GBV-C is presumed to be a novel member of the family Flaviviridae, based 
on its molecular structure, as discussed in chapter 3 of this thesis. Thus, much of 
our current understanding of HGV/GBV-C replication is based on the available 
data from other pesti-and flaviviruses and HCV. A review of the structure and 
genetic characteristics of HGV/GBV-C is contained in the introduction and 
literature review of chapter 3 of this thesis. 
4.2.1 Current understanding of flavivirus replication 
4.2.1.1 Attachment and entry 
Flaviviruses are thought to attach to permissive cells by way of specific cellular 
receptors (227,228). The cellular receptors for flaviviruses, other than HCV, 
remain unknown. CD81 has been shown to be a candidate receptor for HCV 
(229) , and although entry into the cell appears to take place by receptor-mediated 
endocytosis (227,228), these early stages are not well characterised. After entry, 
flavivirus particles have been demonstrated by electron microscopy in cellular 
vesicles from where the nucleocapsid is released into the cytoplasm (230,231). 
From this point in the flavivirus replication cycle, two processes are thought to 
occur in parallel : 
• Production of viral proteins; and 
• RNA replication . 
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4.2.1.2 Protein production 
The positive sense virion RNA is used directly as messenger RNA for synthesis 
of proteins. Translation of the viral proteins begins at an AUG start codon at the 
3' terminal end of the 5'NCR (186). In certain flaviviruses, more than one in-
frame AUG start codon exists, and protein translation occurs from one or more of 
the sites. The 5'NCR acts a regulatory area, providing access for ribosomal entry 
upstream of the single open reading frame (186,205,210). The translation 
process results in the production of a single polyprotein that represents the entire 
flavivirus genome, apart from the 5'- and 3' non-coding regions. This protein 
undergoes post-translational cleavage and modification by both cellular and 
virally encoded proteases, resulting in the formation of mature structural and 
functional components (186). These structural and functional proteins are 
required for the synthesis of new virus particles. As discussed in chapter 3 of this 
thesis, the HGV/GBV-C and GBV-A genomes do not appear to code for a core 
protein, an important distinguishing feature not see in other flaviviruses. 
4.2.1.3 RNA replication 
Native flavivirus RNA molecules have positive polarity. A template for the 
production of further copies of native viral RNA is required, and is believed to be 
mediated by the production of a complementary negative strand of the viral RNA 
(192). The protein responsible for the RNA-dependant RNA polymerase activity 
is coded for in the NS5B region of the genome (203). These negative strand 
RNA molecules are genome-length and facilitate the production of new full length 
mirror image positive strand. These newly formed positive polarity RNA 
molecules are then uti lised for either protein translation or the production of 
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further negative polarity replicative intermediaries ( 192). Synthesis of positive-
and negative strand RNA molecules appears well regulated so as to produce 
fairly constant ratios of positive- to negative viral RNA strands of between 10: 1 
and 100: 1 respectively (232-235). Thus, the presence of these repl icative 
intermediaries in tissues is believed to be indicative of replication and hence 
cellular tropism. The detection of either positive or negative strand RNAs is 
possible by either strand-specific RT-PCR or in-situ hybridisation. (These 
methods are discussed below). 
4.2.1.4 Assembly and release 
It is currently believed that flavivirus RNA and protein synthesis and maturation 
occurs outside of the cell nucleus and that virus protein production is closely 
associated with intracellular membranes (192). For those flaviviruses that are 
readily detectable by electron microscopy, mature viruses are initially visualised 
in the lumen of the endoplasmic reticulum (236). Exocytosis occurs after 
transport of viral components from the endoplasmic reticulum to the cell surface 
(192). 
4.2.2 Methods for detecting flavivirus replication 
Flavivirus replication can be identified by the presence of negative strand viral 
RNA This is possible using one of the following methodologies: 
• Strand-specific RT-PCR (SS-RT-PCR); or 
• In-situ hybridisation (ISH). 
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4.2.2.1 Strand-specific RT-PCR 
Selective detection of positive- or negative strand viral RNA is possible by SS-
RT-PCR (237-239). The process of detecting single strand RNA is technically 
demanding and the published limitations of the technique are discussed below. 
Strand-specific reverse transcription involves the selective conversion of either 
the positive- or negative strand of the genome into cDNA, by means of a single 
primer during the RT process. The residual RNA is subsequently destroyed and 
the RT enzyme inactivated. The process is then followed by conventional PCR 
with resultant selective amplification of one genome strand only. 
The use of SS-RT-PCR is frequently preceded by "standard" non-strand-specific 
RT-PCR of the same tissues. If "standard" RT-PCR is repeatedly performed on 
an organ where replication of that virus does not occur, the PCR will alternate 
between a positive and negative result, due to the "blood contamination" within 
the tissues. However, for those tissues that act as the primary site of viral 
replication, cellular RNA accumulates far in excess of that seen in serum (240), 
and the RT-PCR is consistently positive, due to the vast abundance of viral RNA 
within the cells of that organ. 
Limited work has been performed using SS-RT-PCR for HGV/GBV-C, although 
the methodology has been documented for hepatitis C (237,238). Detecting 
negative strand intermediaries by SS-RT-PCR has been controversial as these 
assays have historically been associated with significant false positive results. 
The first descriptions of SS-RT-PCR used either MMLV or Avian Myeloblastosis 
Virus reverse transcriptase enzymes. These enzymes operate optimally at 
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between 37°C and 42°C. These relatively low operating temperatures resulted in 
the following problems: 
• false priming due to primer binding of the incorrect strand; 
• false priming by extraneous nucleotide sequences; and 
• self-priming of the RNA (238) . 
Three methodologies have been documented to circumvent these problems and 
specifically detect one or other RNA strand. 
A) Currently, the most widely accepted method for strand-specific reverse 
transcription involves the use of the newer heat-stable enzymes such as rTth 
(Perkin-Elmer Cetus) that are active at up to 70°C (238,241). This method 
improves the specificity of the primer binding and reduces the chances of 
extraneous nucleotide sequences binding. In addition the higher 
temperatures support linearisation of complex RNA secondary structures, 
thereby minimising self-priming of the RNA 
B) The second methodology describes the use of "tagged" primers for single 
strand RNA detection (237) . This method incorporates primers with 
extraneous sequences which are added to the 5' end of the desired primer. 
After reverse transcription , the PCR is performed using a primer specific for 
the "tag" region , and not the original viral sequence. 
C) The third method describes the chemical modification of all free 3' ends of the 
RNA with borohydride, thereby preventing them binding to the target RNA 
(242). The strand specific primer is then added after the chemical 
modification process is completed , thereby allowing that primer to bind 
without competition from other nucleotides. 
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In each of these three methods, it remains necessary to denature the RT enzyme 
after completion of the cDNA formation , so as to prevent residual RT activity 
during the PCR process. In addition, certain groups also destroy the residual 
RNA prior to PCR with the addition of RNase. 
4.2.2.2 In-situ hybridisation 
The process of detecting RNA transcripts within the cells of a cut tissue section 
by in-situ hybridisation is well described for both messenger RNA and certain 
viral RNA (243,244). In brief, the in-situ hybridisation process involves the 
generation and use of labeled (e.g. digoxigenin) complementary RNA and/or 
cDNA probes which are applied to the tissue sections. This is followed by 
detection of any bound probe by way of immunological probing for the 
incorporated molecules in the probe. The use of single stranded RNA molecules 
that are complementary to either the negative- or positive strand of a flavivirus 
allows detection of specific strands of RNA 
Successful use of in-situ hybridisation is dependent on a variety of factors, 
including the method of tissue collection, the method of fixing the tissues, and the 
time delay from death to sample collection. It is thought by certain investigators 
that tissue fixing with paraformaldehyde is preferential to formalin or other 
solutions for detecting in-situ RNA (245). The tissues have to be digested and 
processed differently according to the above factors and optimal probe 
concentrations have to be estimated, so as to obtain a sufficient signal in the 
absence of non-specific background signal. As there is no amplification of the 
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RNA/ cDNA prior to detection, the process of in-situ hybridisation is not as 
sensitive as SS-RT-PCR (244). 
The sensitivity of nucleic acid detection in cut biopsy sections is improved if there 
is an in-situ amplification step. In this assay named in-situ PCR, the tissue 
sections are subjected to in-situ RT-PCR using a labeled nucleotide, followed by 
immunological detection of the label as described above for in-situ hybridisation 
(244). 
4.3 Literature review relating to HGV/GBV-C replication 
4.3.1 Overview 
There is a paucity of data on HGV/GBV-C replication site(s) . The overwhelming 
body of data demonstrates the lack of primary hepatotropism of HGV/GBV-C. 
The magnitude of the interest in HGV/GBV-C's role in liver disease has been 
based on: 
• the initial clinical data that suggested that this virus was a causative agent for 
hepatitis; and 
• the knowledge that the causative agent of many sporadic cases of (presumed 
viral) hepatitis is unknown (102,103). 
However, as discussed earlier, it has become clear that there is little (or no) 
evidence to support HGV/GBV-C causing clinical hepatitis (141 ,156,246). 
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4.3.2 Published papers 
Twelve papers have been published to date on the tropism ( or lack thereof) of 
HGV/GBV-C in human tissues (239-241 ,247-255). However, in all but two of 
these papers, only liver and/or mononuclear cells were assessed. 
4.3.2.1 Hepatotropism 
Nine of the above papers present data from studies which attempted to detect the 
presence of HGV/GBV-C replication in liver biopsies, using different 
methodologies (239-241,247-251,253). 
• Six of these nine research projects were unable to detect HGV/GBV-C 
replicative intermediaries using comparable SS-RT-PCR assays 
(239,241,248,249,251,253). 
• The paper by Kobayashi et al. (1999) used SS-RT-PCR to assess circulating 
mononuclear cells and ISH to assess liver biopsies (250). They were able to 
detect HGV/GBV-C negative strand RNA in the liver biopsies of two 
immunosuppressed patients by ISH. However, the ISH assay demonstrated 
the signal to be exclusively from the peri-portal mononuclear cells and not the 
hepatocytes. 
All seven studies therefore concluded that the liver was not the primary site of 
HGV/GBV-C replication. 
Two further studies concluded the same, but based their conclusion on indirect 
evidence (240,247). 
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• Pessoa et al. (1998) investigated relative ratios of HGV/GBV-C RNA in serum 
and liver of infected patients and found that there was no accumulation of viral 
RNA in the liver, as would be expected if there was active replication (240). 
• Berg et al. (1999) assessed the HGV/GBV-C relative viral titres between 
serum and liver tissue, and in addition, examined the viral titre dynamics after 
liver transplantation (247). The liver tissue was negative for HGV/GBV-C 
RNA and the viral kinetics were relatively unchanged in the post-operative 
period. 
Both are highly suggestive that the liver is not the primary site of HGV/GBV-C 
replication. 
4.3.2.2 Tropism of mononuclear cells 
Three studies have assessed the possible tropism of HGV/GBV-C for 
mononuclear cells. Following their positive findings in the mononuclear cells of 
the peri-portal region of liver biopsies, Kobayashi et al. (1999) furthered their 
study to assess circulating mononuclear cells by SS-RT-PCR (250). They found 
two of the six infected individuals studied had evidence of HGV/GBV-C 
replication in these cells. 
These findings contradict the two previous studies (253,254) where a total of 29 
samples were assessed with no evidence of negative strand HGV/GBV-C RNA in 
the circulating mononuclear cells. It is difficult to interpret these conflicting 
results, as most of the studies use different methodologies with varying 
sensitivities and specificities. However, while certain individuals may have a 
subset of circulating mononuclear cells permissive to HGV/GBV-C replication, it 
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appears that in general , circulating mononuclear cells do not represent a primary 
site of HGV/GBV-C replication. 
4.3.2.3 Tropism in extended tissue spectrum 
Two studies (from the same group) have investigated the tissue tropism of 
HGV/GBV-C in a broader range of tissues (252,255). Laskus et al. (1998) 
collected tissues from twelve organs from four HGV/GBV-C infected cadavers 
undergoing post mortem examination and in addition, blood samples from six 
infected living individuals. In the second study, Radkowski et al. (1999) collected 
ten samples from two patients at post mortem examination. The tissues and 
circulating mononuclear cells from both of these two studies were investigated for 
HGV/GBV-C replication. 
It is important to note two factors relating to sample bias in both of these studies: 
• all cadaver tissues from the study by Laskus et al. were from individuals who 
had died of AIDS, and were thus severely immunocompromised. 
• the six blood samples in the Laskus et al study were from HIV1 infected drug 
addicts. 
• The study by Radkowski et al. used samples from two individuals who had 
died of end-stage liver disease. Patients with liver failure are known to be 
immune compromised (256,257). 
The investigators used the same SS-RT-PCR methodology as previously 
described above with the thermostable RT enzyme rTth, and observed the 
following. 
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Laskus et al. study: 
• None of the six blood samples were shown to contain circulating mononuclear 
cells with HGV/GBV-C negative strand RNA. 
• Two out of four of the splenic biopsies and three of the four bone marrow 
biopsies were positive for replicative intermediaries, suggesting these to be 
the major sites of HGV/GBV-C replication. 
• One of four liver biopsies was also positive for negative strand RNA. 
• Where negative strand RNA was detected, 
• it was invariably in the presence of positive strand RNA, and 
• one to two logarithmic counts less concentrated than the positive 
strand RNA. 
• The lymph nodes, pancreas, thyroid , adrenal gland, kidney, lung, muscle, skin 
and spinal cord were not found to contain negative strand HGV/GBV-C RNA 
intermediaries. 
Radkowski et al. study: 
• Both cadavers demonstrated the presence of negative strand RNA in the 
bone marrow and spleen. 
• One of the two cadavers showed evidence of negative strand RNA in the 
lymph node. 
• Where negative strand RNA was detected, it was invariably in the presence of 
positive strand RNA. 
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These studies are a valuable contribution to the HGV/GBV-C data. However, it is 
difficult to extrapolate this data to the general population who have no detectable 
immunosuppression. 
4.3.2.4 HGV/GBV-C permissive cell lines 
Two groups have described human cell lines permissive to HGV/GBV-C 
replication (258,259). Ikeda et al. describe the use of two cell lines: MT-2C, a 
human T-cell leukemia type I-infected cloned T cell line; and PH5CH, a non-
neoplastic human hepatocyte cell line (259). After inoculation of both cell culture 
systems with HCV- and HGV/GBV-C positive serum, both HCV and HGV/GBV-C 
genomes were detected by RT-PCR for more than 30 days. A limitation of the 
study was that HGV/GBV-C was not inoculated into the cells in the absence of 
HCV and therefore propagation of the virus in these systems may be dependent 
on the presence of HCV. 
In the most comprehensive and complete data, Fogeda et al. have shown that 
human peripheral blood mononuclear cells are susceptible to HGV/GBV-C 
infection in-vitro (258). This group used SS-RT-PCR, sucrose ultracentrifugation 
and RNase sensitivity assays, in-situ hybridisation and Western blot assays to 
assess different markers of viral replication, and showed ongoing replication over 
a period of 30 days. 
Although these cell culture systems have been described, there remains no data 
on the intracellular replication strategies of HGV/GBV-C, and thus although not 
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formally shown to date, it is presumed that HGV/GBV-C replicates in the same 
manner as other positive-stranded RNA flaviviruses. 
4.4 Assumptions and hypothesis 
Central to the design and methods employed in this study is the acceptance of 
two factors. 
• The theory that during replication HGV/GBV-C, like other positive stranded 
flaviviruses, replicates its own RNA by way of a negative strand replicative 
intermediary. Thus those tissues permissive to HGV/GBV-C replication would 
have detectable negative strand HGV/GBV-V RNA, and not those tissues 
where no replication occurred. 
• Tissue extracts may be HGV/GBV-C RT-PCR positive due to the detection of 
serum RNA within the tissues. However, in the absence of negative strand 
HGV/GBV-C RNA, this does not indicate viral replication. 
4.5 Study aim 
The aim of this study was to establish the sites of HGV/GBV-C replication in 
multiple cadaver tissue samples collected from individuals who appeared healthy 
before premature violent / traumatic death, using a strand-specific reverse 
transcription PCR assay. 
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4.6 Materials and Methods 
4.6.1 Consent and legal considerations 
Permission for the study was granted by the University of Cape Town Ethics and 
Research Committee. All tissues were collected in terms of the Human Tissues 
Act (Act No 65 of 1983), as amended by the Human Tissue Amendment Act of 
1989. 
4.6.2 Cadaver selection 
Cadaver tissue biopsies were collected during routine post-mortem examination 
at a local city (Maitland) Police Mortuary. This sample collection phase was 
performed in collaboration with Professor G. Knobel and Dr. C. Eedes of the 
University of Cape Town Department of Forensic Medicine and Toxicology. 
4.6.2.1 Cadaver inclusion criteria 
All biopsies were obtained from adult individuals who had died by violent means. 
All adult cadavers examined at the South African Police Service Mortuary in 
Maitland were considered potential candidates for sampling. 
4.6.2.2 Cadaver exclusion criteria 
Cadavers were not recruited to the study if they: 
• had died in hospital (even if admitted for treatment of trauma) ; or 
• were under the age of 18 years; or 
• if there were obvious signs of ante-mortem disease on examination; or 
• if greater than 15 hours had passed between death and post-mortem 
examination. 
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4.6.2.3 Cadaver demographic data 
The following data was recorded from the available information at the mortuary: 
age, gender, cause of death, recorded date and time of death, and time interval 
between death and post-mortem. 
4.6.3 Tissues 
Blood and the following tissue samples and were obtained from the first 12 
cadavers recruited to the study: 
brain, tonsil , submandibular salivary gland, skeletal muscle, heart, lung, 
liver, gall bladder, bone marrow (from ribs) , spleen, kidney, pancreas, 
adrenal, aortic arch, thyroid , lymph node, oesophagus, stomach, small 
intestine, large intestine, gonad, skin and cartilage (from epiglottis). All 
bowel , gall bladder and aortic biopsies were transmural. 
Cadavers recruited subsequent to the initial twelve above had more limited tissue 
samples collected, based on the preliminary analysis of the first group. The 
samples from these subsequent cadavers included blood and the following 
organs: spleen, liver, kidney, skeletal muscle, lymph nodes and adrenal. 
4.6.4 Prevention of RNA carry-over 
The following measures were taken to prevent carry-over of viral RNA between 
biopsies at time of sampling. Each tissue was removed using a scalpel blade 
dedicated to that organ (i .e. 23 blades per cadaver) . Any tissue in contact with 
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the forceps used to hold the tissue was discarded. Each tissue was cut into 1-
2mm3 pieces and placed in separate sealed containers and placed immediately 
on dry ice for transport to a laboratory -80°C freezer. The blood was separated 
by centrifugation and the serum and tissues were kept at -80°C until processed. 
4.6.5 Hepatitis and HIV screening 
Sera of the HGV/GBV-C positive cadavers were screened for antibodies to 
human immunodeficiency viruses (HIV) 1/2, antibodies to hepatitis C virus and for 
hepatitis B surface antigen, using the following Abbott Laboratories automated 
Axsym System assays: 
• HIV "HIV 1/2 gO" 
• HCV 
• HBV surface antigen 
"HCV Version 3.0" 
"HBsAg (V2)" 
4.6.6 Production of synthetic RNA controls 
Synthetic negative- and positive sense control HGV/GBV-C RNA were produced 
as follows. A 343bp PCR product (ZAN22) of the 5'NCR of HGV/GBV-C was 
cloned and sequenced, as previously described in chapter 3 of this thesis. 
4.6.6.1 Negative strand RNA 
For the production of negative strand HGV/GBV-C RNA; the pZAN22 plasmid 
was linearized for one hour at 37°C using 10 units of the restriction enzyme, Sacl , 
so as to produce RNA transcripts of appropriate lengths without excessive 
lengths of RNA complementary to the plasmid. The RNA transcripts were then 
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generated using T7 RNA polymerase and the T7/SP6 Transcription Kit, as 
recommended by the manufacturer (all reagents Roche Molecular Biochemicals, 
Germany). 
4.6.6.2 Positive strand RNA 
Positive strand HGV/GBV-C RNA was produced using the same plasmid 
(pZAN22) after digestion with 10 units of the restriction enzyme Hindlll, as above. 
Transcription of the HGV/GBV-C RNA was then performed using T3 RNA 
polymerase and the buffers and reagents contained in the T7 /SP6 Transcription 
Kit (as above). 
Template DNA from both reactions was then removed by incubating the reaction 
at 37°C for 30 minutes with 1 O units RNase-free DNase (Roche Molecular 
Biochemicals, Germany). Plasmid destruction was confirmed by performing PCR 
(as described below) on the synthetic RNA without RT. The synthetic RNA was 
quantified using the Beckman DU-40 spectrophotometer (Beckman Coulter Inc., 
California, USA), aliquotted into 5µ1 amounts and stored at -80°C until required. 
4.6.7 Tissue and control RNA processing 
4.6.7.1 RNA Extraction 
Serum: 
Total RNA was extracted from cadaver serum, as previously described in chapter 
2 of this thesis. 
Tissues: 
RNA from tissue biopsies was extracted in a similar manner as described for 
serum. Each biopsy of 1-2mm3 was macerated in a petri dish using a scalpel 
137 
blade dedicated to that tissue and then resuspended in 200µ1 of DepC treated 
water. This cell suspension was added to 1 ml Total RNA Isolation Reagent 
(Advanced Biotechnologies Ltd, London, UK), vortexed for 30 seconds and then 
processed in the same way as serum samples. The extracted RNA was then 
resuspended in 50µ1 DepC treated water. 
Four splenic and four bone marrow HGV/GBV-C PCR negative biopsies were 
also included and subjected to the same RT-PCR to ensure that there was no 
non-specific amplification of genetic material. 
4.6.8 Reverse Transcription 
Two reverse transcription reactions were utilised for the serum and tissue 
biopsies. 
4.6.8.1 Non strand-specific reverse transcription 
The extracted RNA from all biopsies was subjected to reverse transcription using 
random hexamer primers and MMLV RT, as previously described in chapter 2 of 
this thesis. This was followed by HGV/GBV-C PCR as below, so as to determine 
whether any (negative- or positive strand) HGV/GBV-C RNA was present. 
These results were interpreted as follows: 
1. Any extracted tissue sample that was HGV/GBV-C negative was re-tested to 
confirm that the RNA extraction and RT were successful. This was done by 
performing an RT-PCR assay for the presence of beta-actin mRNA, as 
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previously described (260). Samples that were found to be HGV/GBV-C 
negative and beta-actin messenger RNA positive were not tested further. 
2. Samples found to be HGV/GBV-C positive by this non strand-specific reaction 
were then assessed for the presence of specific RNA strands, by the method 
below. Both positive- and negative strand synthetic RNA controls were 
included in every SS-RT-PCR batch to ensure the strand specificity of the 
assay. 
4.6.8.2 Strand-specific reverse transcription: 
All HGV/GBV-C PCR positive RNA extracts were assessed to discriminate 
between negative- and positive strand HGV/GBV-C RNA, by strand-specific RT-
PCR using the newly developed Thermoscript™ RT enzyme system (GibcoBRL, 
USA). 
Denaturation: 
Five microlitres of extracted RNA was added to 5µ1 DepC treated water 
containing 50pmol of either the sense or antisense primer (below) and heated at 
65°C for five minutes. 
Reverse transcription: 
A 1 OµI solution containing 1 X cDNA synthesis buffer, 1 OmM dithiothreitol, 40U 
RNaseOUT™ RNase inhibitor, 2mM dNTP mix, and 7.5U Thermoscript™ RT 
enzyme was added to the heated RNA and incubated at 65°C for one hour. 
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Reverse transcriptase inactivation: 
The reverse transcriptase enzyme was then heat inactivated at 85°C for 5 
minutes. 
RNA destruction: 
One unit of RNase H was added to destroy any residual RNA and incubated at 
37°C for 20 minutes. 
4.6.9 Polymerase chain reaction 
A nested HGV/GBV-C PCR was performed, as previously described in chapter 3 
of this thesis, using the following primers: 
Sense 5' -TGGT AGGTCGT AAA TCCCGGT-3' 
Anti sense 5' -GGAGCTGGGTGGCCCCATGCAT-3' 
Nested sense 5' -GGT AGCCACT ATAGGTGGG-3' 
Nested antisense 5' -CTCGGTIT AACGGCGACGCT-3' 
Using these primers, a positive result was predicted to generate a final PCR 
amplicon fragment of 136bps. 
Amplicon visualisation 
PCR products were separated by electrophoresis in 2% agarose gel and 
visualised under ultra-violet light using ethidium bromide staining. 
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4.7 Results 
4. 7 .1 Cadavers 
Forty-five cadavers were recruited to the study of which four were HGV/GBV-C 
RNA positive on serum analysis. The ante-mortem demographic data of the PCR 
positive individuals is displayed in Table 4.1. Of note, all four cadaver sera were 
anti-HIV negative and anti-HCV negative, while one was hepatitis B surface 
antigen positive. None showed any obvious signs of clinical disease at post 
mortem. 
Table 4.1: Demographic data of HGV/GBV-C positive cadavers. 
Age 30 36 25 45 
Gender Male Female Male Male 
Cause of death Gunshot MVA* Gunshot Stab 
12 hours 7 hours 8 hours 14 hours 
Negative Negative Negative Negative 
Negative Positive Negative Negative 
Negative Negative Negative Negative 
* = motor vehicle accident 
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4.7.2 Tissues collected 
Cadavers 1 and 2 had biopsies taken from serum and 23 organs. Serum and six 
tissues were obtained from the latter two cadavers. These tissues are shown in 
Table 4.2. 
4. 7 .3 The assay 
4.7.3.1 RT-PCR sensitivity 
The RT-PCR assay sensitivity for synthetic RNA was shown to be 150 RNA 
copies per mililitre. 
4.7.3.2 Reverse transcription specificity 
The SS-RT-PCR assay was capable of specific amplification of either positive- or 
negative strand synthetic HGV/GBV-C RNA copies over a concentration of five 
logarithms per mililitre. 
4. 7 .4 Non strand-specific RT-PCR 
Multiple tissues from each cadaver were HGV/GBV-C PCR positive when 
performing the RT reaction with random hexamers and MML V RT as described 
below and shown in Table 4.2. 
4.7.4.1 Cadaver 1 
The following tissues were PCR positive for cadaver 1: serum, skeletal muscle, 
tonsil, lymph nodes, liver, spleen, kidney, adrenal and bone marrow. 
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4.7.4.2 Cadaver 2 
Cadaver 2 was found to be PCR positive in serum, skeletal muscle, heart muscle, 
thyroid , salivary gland, lung, lymph nodes, liver, spleen, kidney, adrenal, aorta, 
and bone marrow. 
4.7.4.3 Cadavers 3 and 4 
Cadavers 3 and 4 were both PCR positive in serum and all six biopsies taken at 
post-mortem. 
4.7.4.4 HGV/GBV-C RT-PCR negative tissues 
Table 4.2 also displays the tissues found to be RT-PCR negative, thereby 
excluding the presence of both negative and positive strand HGV/GBV-C RNA 
All of these HGV/GBV-C PCR negative tissues were positive for beta-actin 
messenger RNA, thereby confirming that the RNA extraction and RT reaction 
were successful. 
4.7.5 Strand-specific RT-PCR 
4.7.5.1 Serum 
None of the serum samples had detectable negative strand RNA by strand-
specific RT-PCR. 
4.7.5.2 Tissues 
All four splenic and both bone marrow biopsies were strongly positive for both 
positive- and negative sense HGV/GBV-C RNA (Table 4.2) . In addition, 
replicative intermediaries were found within the kidney of cadaver 3 and the liver 
of cadaver 4. 
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However, although positive strand HGV/GBV-C RNA was detected in the other 
tissues, no signal for negative strand HGV/GBV-C RNA was obtained. This 
suggests that the PCR signals were not due replication of the virus within tissues, 
but rather due to serum HGV/GBV-C RNA. Although relative titres of positive-
and negative strands were not formally assessed, the intensity of the gel bands 
was greater for positive strand RNA than negative strand. 
Although both bone marrow and spleen were strongly positive for replicative 
intermediaries, other lymphoid tissues such as tonsil and lymph nodes were 
negative. Cadavers 1 and 2 show no signs of positivity in any part of the bowel 
(including gall bladder and pancreas) and were thus not tested further for specific 
strands. The same applies to the testis and ovary of cadaver 1 and 2 
respectively that were both RT-PCR negative. The sections of bowel and gall 
bladder tissue were transmural, and would thus have contained a variety of cell 
types including epithelium, mucous glands, muscle and lymph vessels (and 
residual bowel contents) . The more vascular tissues, such as adrenal, muscle, 
liver and kidney were more likely to be PCR positive in the first RT-PCR using 
MMLV RT, but only showed positive strand RNA when using the supplementary 
SS-RT-PCR. 
No amplicons were generated from the four splenic and bone marrow biopsies 
taken from HGV/GBV-C negative cadavers. 
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Table 4.2 gives a summary of the above results. Tissues found to repeatedly 
contain negative strand HGV/GBV-C RNA are shaded. 
Table 4.2: Summary of tissues collected and results obtained. 
Cadaver1 Cadaver 2 
Random Positive Negative Random Positive Negative 
Hexamers strand strand Hexamers strand strand 
Serum Pos y N Serum Pos y N 
Brain Neg Brain Neg 
Skeletal muscle Pos y N Skeletal muscle Pos y N 
Heart muscle Neg Heart muscle Pos y N 
Thyroid Neg Thyroid Pos y N 
Salivary gland Neg Salivary gland Pos y N 
Tonsil Pos y N Tonsil Neg 
Lung Neg Lung Pos y N 
Lymph nodes Pos y N Lymph nodes Pos y N 
Liver Pos y N Liver Pos y N 
Gall bladder Neg Gall bladder Neg 
Spleen Pos y y Spleen Pos y y 
Kidney Pos y N Kidney Pos y N 
Pancreas Neg Pancreas Neg 
Oesophagus Neg Oesophagus Neg 
Stomach Neg Stomach Neg 
Small bowel Neg Small bowel Neg 
Large bowel Neg Large bowel Neg 
Adrenal gland Pos y N Adrenal gland Pos y N 
Ovary I testis Neg Ovary I testis Neg 
Aortic arch Neg Aortic arch Pos y N 
Skin Neg Skin Neg 
Cartelage Neg Cartelage Neg 
Bone marrow fk'"+;~~J,':; ;, ;J,~;\y ;1":,);;;Y . .. , Bone marrow · Pos y y . "\ ·, ., 
Cadaver 3 Cadaver4 
Serum Pos y N Serum Pos y N 
Skeletal muscle Pos y N Skeletal muscle Pos y N 






y Liver Pos y N . ,r .... 
Spl~n ;•, •+;.:<%<if, 1,'::.,,.r Spleen . Pos y y .. ·'·· 
Kidney y N Kidney Pos y y 
Adrenal gland Pos y N Adrenal gland Pos y N 
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Agarose gel photograph 
Figure 4.1 is an example from the results of cadaver number 1. Each control or 
specimen is contained in two consecutive lanes. In lanes 2, 4, 6, 8, 10, 12 and 
14 the reverse transcription reaction was performed with the sense primer (S). In 
lanes 3, 5, 7, 9, 11, 13 and 15 the reverse transcription reaction was performed 
with the antisense primer (aS). Lanes 2 and 3 show the results of positive strand 
control RNA, and lanes 4 and 5 show the results of the negative strand control 
RNA. Thereafter lanes 6-15 contain the results of the specified tissues. Lanes 1 
and 16 contain molecular weight marker VI (Roche Molecular Diagnostics, 
Germany). 
Figure 4.1: Agarose gel of SS-RT-PCR results from cadaver 1. 
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4.8 Discussion 
This study is the first to document the sites of HGV/GBV-C replication in infected 
subjects without obvious disturbance of the immune system and in addition, 
increases the spectrum of tissues examined to date. 
4.8.1 Tissue samples 
4.8.1.1 Serum 
Serum samples from each of the four HGV/GBV-C infected cadavers was RT-
PCR positive using MMLV RT. However, strand-specific RT-PCR on the same 
serum samples showed only positive strand RNA and not negative strand RNA 
Thus all further results for negative-strand RNA in tissue samples reflect 
intracellular RNA and not serum contamination. 
4.8.1.2 Lymphoid tissues 
All four splenic and both bone marrow biopsies were strongly positive for both 
negative- and positive strand RNA, suggesting that these represent the primary 
sites of HGV/GBV-C replication. The cell-specificity suggested by these cadaver 
findings is remarkably narrow, as seen by the negative findings in lymph node 
and tonsil biopsies. The data indicate that there is a primary cell tropism of 
HGV/GBV-C limited to the cells of the bone marrow and spleen and not a broad 
lymphotropism. The candidate cells for this tropism include the haematological 
stem cells, 8-cells, plasma cells and mononuclear phagocytes, but almost 
certainly excludes the T-cells that predominate in the lymph nodes and tonsils. 
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4.8.1.3 Liver and kidney 
Negative strand RNA transcripts were also consistently found in the liver of one 
cadaver and in the kidney of another. This may suggest that a subgroup of those 
infected may have low levels of replication within these two organs. 
4.8.2 Comparison with literature 
4.8.2.1 Extended tissue spectrum 
There is remarkable consistency between our data and that previously generated 
from patients who died of AIDS or end-stage liver disease (252,255) suggesting 
that, unlike many viral infections which disseminate in immunocompromised 
individuals, HGV/GBV-C is unable to disseminate, on account of its high cell-
specificity. However, although the study designs presented in this thesis and 
those of Laskus et al. and Radkowski et al. are similar, one potentially significant 
difference is that the other two studies allowed collection of cadaver tissue 
samples for up to 48 hours after death. The stability of intracellular HGV/GBV-C 
RNA over this prolonged time interval is unknown, and this factor may have led to 
under-reporting of the sites permissive to HGV/GBV-C replication in 
immunocompromised patients. 
4.8.2.2 Liver and kidney 
The overwhelming majority of biopsies assessed in the literature show no 
evidence of liver replication and the two studies that investigated the kidney 
(252,255) did not show evidence of replication. Insights obtained from the 
Kobayashi et al. data (250) and these findings in spleen, bone marrow, liver and 
kidney may lend assistance in interpreting these findings. Their study 
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demonstrated the presence of HGV/GBV-C replicative intermediaries in the 
mononuclear cells of the portal tract but not in hepatocytes. It is possible that the 
positive signal in liver and kidney is due to peri-portal macrophages in the liver 
(possibly Kuppfer cells) and their renal mononuclear counterparts, the mesangial 
cel ls. As strand-specific RT-PCR does not allow discrimination between the 
different cells of the biopsy, these positive findings represent the summation of 
the cellular components of each biopsy and thus may be due to any one of the 
cellular components. 
4.8.3 HGV/GBV-C infection and haematological disturbances 
The consistent presence of HGV/GBV-C replicative intermediaries in two 
lymphoid tissues allows the focus of future studies to move away from the liver so 
as to investigate the possible role of this virus in haematological abnormalities. 
The data contained in this chapter does not in any way suggest that HGV/GBV-C 
is pathogenic. However, if HGV/GBV-C does have a pathogenic role, the effect 
may be seen in the organs where replication is detectable. 
The role of HGV/GBV-C in haematological disorders has received little attention 
to date and has focussed mainly on the acquisition of HGV/GBV-C during 
transfusions and transplantation (176,261 -263). Although a few epidemiological 
studies have assessed the association of HGV/GBV-C infection and 
haematological disturbances, the data are inconclusive (264,265), and larger 
studies are required to supplement this. 
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4.8.4 Transmission and risk factors 
It is clear that HGV/GBV-C is transmitted by blood (106,141,263). However, 
many infections occur in the absence of a known risk factor. In attempting to 
elucidate other transmission modes, it is important to note certain tissues that 
were negative for replicative intermediaries. 
4.8.4.1 Saliva 
HGV/GBV-C has previously been detected in saliva and transmission by this 
mode has been postulated (109,266). This data suggests that any detectable 
virus in saliva is not due to replication in the salivary glands. It is possible that, as 
in the case of HIV (267), HGV/GBV-C may be present in the saliva of infected 
individuals, but not normally transmitted by this route. 
4.8.4.2 Gastrointestinal tract 
Samples from the entire gastrointestinal tract from oesophagus to large bowel 
(apart from the liver of cadaver 3) were shown to be non-permissive to 
replication. These biopsies were transmural , and therefore contained all cellular 
components of the bowel (and any attached bowel contents on the inner surface). 
These findings suggest that it is unlikely that the bowel (or its contents) is 
involved in transmission or acquisition of HGV/GBV-C. 
4.8.4.3 Sexual 
It has been postulated that HGV/GBV-C may be sexually transmitted 
(114,115,268,269), and evidence suggests that the receptive sexual partner may 
be at greater risk of acquiring the infection (114). Sexual transmission may well 
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occur. However, this data is highly suggestive that the ovary and testis are not 
involved in virus replication and thus indirect transmission by sexual contact. 
4.8.5 Assay reliability 
The SS-RT-PCR process is technically demanding and has previously been 
associated with false positivity due to self priming of the RNA, false priming of the 
incorrect RNA strand and residual RT activity of enzymes during PCR (237,270). 
Much of the limitation was reverse transcriptase enzyme related. It is evident that 
the problems experienced were mainly due to the low operating temperatures of 
the enzymes available, and thus the advent of newer thermostable equivalents 
has resulted in increased specificity (237,271). 
The assay used in this study was optimised using synthetic HGV/GBV-C RNA as 
template and showed repeatedly specific results over significantly different RNA 
concentrations when using the Thermoscript™ RT (GibcoBRL, USA) at 
temperatures at or above 65°C. Thus like with the use of the enzyme rTth , 
strand-specific results are possible with Thermoscript™ RT without the tagging of 
primers (237) or chemical modification of the 3' ends of RNA (242). 
Thus, in summary, this study has assessed multiple biopsy specimens from 
apparently healthy individuals who died violent or traumatic deaths. The 
consistent finding of HGV/GBV-C replicative intermediaries in the spleen and 
bone marrow of these infected individuals suggests that these two organs 
represent the primary sites of HGV/GBV-C replication. 
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Chapter 5 
Summary and Recommendations 
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The prevalence of serological markers of hepatitis A and B infection has been 
shown to be high amongst the adult Black communities of the Western and 
Eastern Cape provinces of South Africa. Although the data on hepatitis A is 
comparable with statistics generated in other regions of South Africa, the 
exposure rate to hepatitis B is lower than previously documented. The morbidity 
associated with hepatitis A infection currently remains extremely low in these 
communities, and thus new government sponsored intervention strategies to . 
prevent infection do not appear necessary. However, it has to be borne in mind 
that, in the future with the upgrading of social services and living conditions of 
many previously disadvantaged communities, fewer individuals will be exposed to 
hepatitis A in early life, and thus will have a greater chance of a symptomatic 
infection later. 
The prevalence of hepatitis B, although lower than other regions, remains 
unacceptably high and current strategies to vaccinate all children against 
hepatitis B as part of the Expanded Program on Immunisation should continue. 
In doing so, the long-term consequences of hepatitis B infection such as cirrhosis 
and hepatocellular carcinoma will be prevented. This strategy will also ensure 
that the hepatitis D virus is not introduced into the South African population. 
Hepatitis C virus continues to be prevalent in these communities, and to a greater 
extent than that seen in the blood transfusion services. Preventing infection 
through adequate screening of blood products is essential, and is already in 
place. Further interventions to limit the spread of hepatitis C remain difficult, 
while the mechanisms of spread in the broader community remain unclear. The 
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health authorities should continue providing the infra-structure to monitor and 
treat those with cirrhosis and hepatocellular carcinoma induced by hepatitis C. In 
the interim, research projects investigating potential hepatitis C vaccines should 
be supported. 
Hepatitis E virus exposure differs significantly between communities, with the 
poorest rural communities at greatest risk of acquiring the disease, because of 
inadequate access to chlorinated water and water-borne sewerage disposal. The 
hepatitis E virus data contained in this thesis have been presented to the Ministry 
of Water Affairs and Forestry of the South African Government. Subsequent to 
this presentation, the Ministry launched a government-sponsored water provision 
project in the rural village of Keiskammahoek, as a part of a broader program to 
improve the lives of these communities. The provision of chlorinated water to 
Keiskammahoek offers an opportunity to re-investigate the community at a later 
date to assess the potential favourable impact of this water provision. 
HGV/GBV-C carriage was found to be high. The associations between infection 
and living in an urban setting, younger age and the use of illicit (non intra-venous) 
drugs are noteworthy. Recommendations to prevent infection must remain 
guarded in the setting of no definable, validated disease association described to 
date. 
This molecular characterisation of South African HGV/GBV-C variants has shown 
two significant differences from those isolates previously described. Firstly, the 
majority of South African isolates are genetically different from those described in 
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West Africa and other geographic regions, requiring subdivision into a separate 
fourth genotype. If a disease association is documented and validated for 
HGV/GBV-C, it will be necessary to confirm that the findings are true for 
genotype 4 as well. Secondly, the S'NCR of a minority of these isolates have a 
major deletion over domains II and Ill of the proposed RNA secondary structure, 
suggesting that this segment of the S'NCR is non-essential for maintenance of 
the internal ribosomal entry site. However, these variants were not found in the 
absence of wild-type HGV/GBV-C, thus raising the possibility that these mutant 
viral RNA copies are not in fact replication competent. The finding of these 
deletion isolates offers an opportunity for further studies of ribosomal binding, by 
way of translation assays comparing deletant non-coding regions with the wild-
type prevalent in South Africa. 
The accumulated clinical and laboratory evidence has demonstrated that the 
initial presumed association with liver disease is incorrect. The liver does not act 
as the primary site of replication for HGV/GBV-C and there is no detectable liver 
disease in the presence of viraemia. This study has more organs tested than any 
other study to date. In addition, these are the only results generated from 
biopsies taken from individuals without of end-organ failure or AIDS. The data 
add to that of Laskus et al. (1998) and Radkowski et al. (1999) showing the sites 
of replication to be the bone marrow and spleen. 
The viruses (both HGV and GBV-C) have a nomenclature and an association that 
was unfortunately linked to liver disease before this was proven. Thus, on the 
basis of our and other accumulated data, it is suggested that the use of the 
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names "the Hepatitis G Virus" and "GBV-C" both be limited in scientific 
publications, until formal naming and placing of the virus within the unified 
taxonomy system of the International Committee on Taxonomy of Viruses. 
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Appendix 
Appendix 1 Keiskammahoek Districts 
1. Keiskammahoek Town 
2. Bomapass 
3. Elukhanyweni 
4. Cata I 
5. Cata II 
6. Upper Mnyameni 
7. Lower Mnyameni 
8. Upper Gxulu 
9. Lower Gxulu 
10. Bumbane 
11. Ngxalawe I 










21 . Ndema's Farm 
22. Dontsa 
23. Pierie Saw Mills 
24. Fair View 
25. Evelyn Valley 
26. Sandi le Purification 
27. Fort Cox 
28. Lower Zingcuka 
29. Madubela 
30. Sonjika's Farm 







38. Upper Ngqumeya 
39. Lower Ngqumeya 
40. Upper Zingcuka 
41 . Peter's Farm 






MEDIA, ANTIBIOTICS, BUFFERS AND SOLUTIONS 
























Solvent = water 
working cone. = 1 OOµg/ml 
Store at -20°C 
3: BUFFERS AND SOLUTIONS 
CHLOROFORM-ISOAMYLALCOHOL 
Mix at a ratio of 24: 1 
DEPC-TREATED WATER (0.1%) 
DEPC 
Distilled water 
Stir for 30 min. at RT, then autoclave 
ETHIDIUM BROMIDE (EtBr) 
EtBr 
Distilled water 
Shake well to dissolve 





















NEUTRALISATION BUFFER (1M ammonium acetate, 20 mM NaOH) 
NaOH 8.0g 
Tris-HCI (1 M, pH 7.2) 770.8g 
EDTA (0.5M, pH 8.0) to 10 L 




Adjust pH to 7. 5 with 1 ON Na OH and autoclave 
WASHING BUFFER 3 
Tris-HCI (1 M, pH 9.5) 
NaCl (5M) 









BLOCKING BUFFER (1%) 
Blocking reagent 
Washing Buffer 1 




Blocking stock solution (10%) 
Distilled water 
SODIUM DODECYL SULPHATE (SDS) (10%, wlv) 
sos 
Distilled water 
Heat to+/- 80°C to dissolve 
Add HCL to pH7.2 
20X STANDARD SODIUM CITRATE (SSC) 
NaCl 
Sodium citrate 
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